ClinicalTrials.gg
TerminatedNCT04115839PENGUIN 2Updated Mar 18, 2022Results posted

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy

A Phase 3 interventional study of Filgotinib and Placebo to match filgotinib in Psoriatic Arthritis, sponsored by Gilead Sciences. Terminated at 59 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-03-18.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Why this study was terminated
Development program terminated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 193 studies in Arthritis, Psoriatic with a site in United States — 29 open to participants now, 59 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.

Enrollment
109th of 158
106 · median 237
Started
2019
with 16 others
Phase 3
71 of 193
4 open now
Registered
114th of 193
by date

Among the 193 studies in Arthritis, Psoriatic with a site in United States, this one is the 109th largest by enrollment of the 158 interventional ones that give a count, is one of 17 that started in 2019, is one of 71 in phase 3, and was the 114th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

29 of the 193 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Arthritis, Psoriatic with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the American College of Rheumatology 20% improvement (ACR20) response in participants with active psoriatic arthritis who have an inadequate response or are intolerant to biologic disease-modifying anti-rheumatic drugs (DMARD) therapy.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female participants who are 18-75 years of age (19-75 years of age at sites in Republic of Korea, 20-75 years of age at sites in Japan and Taiwan), on the day of signing initial
  • Meet Classification Criteria for Psoriatic Arthritis (CASPAR)
  • Have a history consistent with Psoriatic Arthritis (PsA) ≥ 6 months at Screening
  • Have active PsA defined as ≥ 3 swollen joints (from a 66 swollen joint count [SJC]) and ≥ 3 tender joints (from a 68 tender joint count [TJC]) at Screening and Day 1; these may or may not be the same joints at Screening and Day 1
  • Must have a documented history or active signs of at least one of the following at Screening

    • Plaque psoriasis
    • Nail changes attributed to psoriasis
  • Have had inadequate response (lack of efficacy after ≥ 12 week duration of therapy) or intolerance to at least one and not more than 3 biologic DMARDs (bioDMARD) administered for the treatment of PsA or psoriasis, as per local guidelines / standard of care
  • Prior to the first dose of study drug on Day 1, treatment with bioDMARD(s) should have been discontinued

Key Exclusion Criteria:

  • Prior exposure to a janus kinase (JAK) inhibitor > 2 doses
  • Any active / recent infection
  • Any chronic and / or uncontrolled medical condition that would put the individual at increased risk during study participation or circumstances which may make a individual unlikely or unable to complete or comply with study procedures and requirements, per investigator judgement
  • Any moderately to severely active musculoskeletal or skin disorder other than PsA or plaque psoriasis that would interfere with assessment of study parameters, as per judgement of investigator

NOTE: Prior history of reactive arthritis or axial spondyloarthritis is permitted if there is documentation of change in diagnosis to PsA or additional diagnosis of PsA

  • Any history of an inflammatory arthropathy with onset before age of 16 years old
  • Active disease that would interfere with assessment of study parameters or increase risk to the individual by participating in the study, (e.g. uveitis, inflammatory bowel disease, uncontrolled thyroiditis, systemic vasculitis, transverse myelitis), per judgement of investigator
  • Pregnancy or nursing females
  • Active drug or alcohol abuse, as per judgement of investigator

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Filgotinib 200 mg (Main Study)

    Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.

    Drug: Filgotinib · Drug: Placebo to match filgotinib

  • Experimental
    Filgotinib 100 mg (Main Study)

    Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 16 weeks.

    Drug: Filgotinib · Drug: Placebo to match filgotinib

  • Placebo comparator
    Placebo (Main Study)

    Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.

    Drug: Placebo to match filgotinib

  • Experimental
    Filgotinib 200 mg (LTE)

    Participants will receive filgotinib 200 mg + PTM filgotinib 100 mg for up to 44 weeks.

    Drug: Filgotinib · Drug: Placebo to match filgotinib

  • Experimental
    Filgotinib 100 mg (LTE)

    Participants will receive PTM filgotinib 200 mg + filgotinib 100 mg for up to 44 weeks.

    Drug: Filgotinib · Drug: Placebo to match filgotinib

Interventions

  • Tablets will be administered orally once daily with or without food.

    Also known as: GS-6034, GLPG0634

  • DrugPlacebo to match filgotinib

    Tablets administered orally once daily with or without food.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement Response at Week 12

    ACR20 response is achieved when the participant has: ≥ 20% improvement (reduction) from baseline in tender joint count based on 68 joints (TJC68), swollen joint count based on 66 joints (SJC66) and in at least 3 of the following 5 items: patient's global assessment of disease activity (PGADA) using a visual analogue scale (VAS) on a scale of 0 (very well) to 100 (very poor); physician's global assessment of disease activity (PHGADA) using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity); health assessment questionnaire-disability index (HAQ-DI) inclusive of activities scored on a scale of 0 (no disability) to 3 (completely disabled); HAQ-DI pain assessment using VAS on a scale of 0 (no pain) to 100 (serious pain), and high-sensitivity C-reactive protein (hsCRP).

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 4 and 16

    PASDAS is a composite disease activity measure for psoriatic arthritis. The PASDAS includes the following components: PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\]; PhGADA \[using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity)\]; 36-item short form survey (SF-36) \[a questionnaire which measures quality of life across eight domains used to determine a physical component summary (PCS) with a score range of 0-100, higher scores indicates better health status\]; TJC68; SJC66; leeds enthesitis index (LEI) \[assessed at 6 sites with a score range of 0 to 6, higher scores indicates higher degree of enthesitis\]; Tender dactylitis count (TDC) \[with a score range of 0 to 60, higher score indicates higher degree of dactylitis\]; C-reactive protein (CRP). The score of PASDAS ranges from 0-10, lower scores indicates better function. A negative change from baseline indicates improvement.

    Time frame: Baseline, 4, and 16 weeks

  2. Change From Baseline in PASDAS at Week 48

    PASDAS is a composite disease activity measure for psoriatic arthritis. The PASDAS includes the following components: PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\]; PhGADA \[using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity)\]; 36-item short form survey (SF-36) \[a questionnaire which measures quality of life across eight domains used to determine a physical component summary (PCS) with a score range of 0-100, higher scores indicates better health status\]; TJC68; SJC66; leeds enthesitis index (LEI) \[assessed at 6 sites with a score range of 0 to 6, higher scores indicates higher degree of enthesitis\]; Tender dactylitis count (TDC) \[with a score range of 0 to 60, higher score indicates higher degree of dactylitis\]; C-reactive protein (CRP). The score of PASDAS ranges from 0-10, lower scores indicates better function. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 48

  3. Percentage of Participants Who Achieved Minimal Disease Activity (MDA) Response at Weeks 4, 8, 12, and 16

    MDA is a measure to indicate disease remission, and is based on a composite score of 7 domains. A participant is considered as having achieved the MDA if the participant fulfills at least 5 of the following 7 criteria: TJC68 ≤1; SJC66 ≤1; Psoriatic arthritis disease activity score (PASI) ≤1 for participants with psoriasis covering BSA \<3% \[PASI evaluates the severity and extent of psoriasis. In PASI, body is divided into four parts, head and neck, upper limb, trunk and lower limbs. Each area is assessed for erythema, induration and scaling, each rated on a scale of 0 to 4. The total score ranges from 0 (no disease) to 72 (maximal disease)\]; PGAPI ≤15 \[using VAS on a scale of 0 (no pain) to 100 (serious pain)\]; PGADA ≤20 \[using VAS on a scale of 0 (very well) to 100 (very poor)\]; HAQ-DI score ≤0.5; LEI score ≤1 for participants with enthesitis at baseline.

    Time frame: Weeks 4, 8, 12, and 16

  4. Percentage of Participants Who Achieved MDA Response at Weeks 20, 24, 28, 36, and 48

    MDA is a measure to indicate disease remission, and is based on a composite score of 7 domains. A participant is considered as having achieved the MDA if the participant fulfills at least 5 of the following 7 criteria: TJC68 ≤1; SJC66 ≤1; Psoriatic arthritis disease activity score (PASI) ≤1 for participants with psoriasis covering BSA \<3% \[PASI evaluates the severity and extent of psoriasis. In PASI, body is divided into four parts, head and neck, upper limb, trunk and lower limbs. Each area is assessed for erythema, induration and scaling, each rated on a scale of 0 to 4. The total score ranges from 0 (no disease) to 72 (maximal disease)\]; PGAPI ≤15 \[using VAS on a scale of 0 (no pain) to 100 (serious pain)\]; PGADA ≤20 \[using VAS on a scale of 0 (very well) to 100 (very poor)\]; HAQ-DI score ≤0.5; LEI score ≤1 for participants with enthesitis at baseline.

    Time frame: Weeks 20, 24, 28, 36, and 48

  5. Percentage of Participants Who Achieved Very Low Disease Activity (VLDA) Response at Weeks 4, 8, 12, and 16

    VLDA is a measure to indicate disease remission, and is based on a composite score of 7 domains. A participant is considered as having achieved the VLDA if the participant fulfills all the seven criteria: TJC68 ≤1; SJC66 ≤1; PASI score ≤1 for participants with psoriasis covering BSA \<3% \[PASI evaluates the severity and extent of psoriasis. In PASI, body is divided into four parts, head and neck, upper limb, trunk and lower limbs. Each area is assessed for erythema, induration and scaling, each rated on a scale of 0 to 4. The total score ranges from 0 (no disease) to 72 (maximal disease)\]; PGAPI ≤15 \[using VAS on a scale of 0 (no pain) to (serious pain)\]; PGADA ≤20 \[using VAS on a scale of 0 (very well) to 100 (very poor)\]; HAQ-DI score ≤0.5; LEI score ≤1 with participants with enthesitis at baseline.

    Time frame: Weeks 4, 8, 12, and 16

  6. Percentage of Participants Who Achieved VLDA Response at Weeks 20, 24, 28, 36, and 48

    VLDA is a measure to indicate disease remission, and is based on a composite score of 7 domains. A participant is considered as having achieved the VLDA if the participant fulfills all the seven criteria: TJC68 ≤1; SJC66 ≤1; PASI score ≤1 for participants with psoriasis covering BSA \<3% \[PASI evaluates the severity and extent of psoriasis. In PASI, body is divided into four parts, head and neck, upper limb, trunk and lower limbs. Each area is assessed for erythema, induration and scaling, each rated on a scale of 0 to 4. The total score ranges from 0 (no disease) to 72 (maximal disease)\]; PGAPI ≤15 \[using VAS on a scale of 0 (no pain) to (serious pain)\]; PGADA ≤20 \[using VAS on a scale of 0 (very well) to 100 (very poor)\]; HAQ-DI score ≤0.5; LEI score ≤1 with participants with enthesitis at baseline.

    Time frame: Weeks 20, 24, 28, 36, and 48

  7. Change From Baseline in Disease Activity in Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, and 16

    DAPSA is calculated by summing the following components: TJC68; SJC66; PGADA \[using VAS on a scale of 0 (very well) to 100 very poor)\]; PGAPI \[using a VAS on a scale of 0 (no pain) to 100 (serious pain)\] and CRP. DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. A negative change from baseline indicates improvement.

    Time frame: Baseline, 2, 4, 8, 12, and 16 weeks

  8. Change From Baseline in DAPSA at Weeks 18, 20, 24, 28, 36, 48, and 60

    DAPSA is calculated by summing the following components: TJC68; SJC66; PGADA \[using VAS on a scale of 0 (very well) to 100 very poor)\]; PGAPI \[using a VAS on a scale of 0 (no pain) to 100 (serious pain)\] and CRP. DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. A negative change from baseline indicates improvement.

    Time frame: Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks

  9. Change From Baseline in Physician's Global Assessment of Psoriasis (PhGAP) at Weeks 2, 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the Body Surface Area (BSA) at Baseline

    The PhGAP is used to determine the participant's psoriasis lesions overall at a given time point. The participant's psoriasis disease activity is assessed by a physician according to the grades of induration, erythema, and scaling on a scale of 0 to 5. The sum of the three grades is used to obtain the total average score. PhGAP is based on the total average score on a scale of 0-5 where, 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate, 4 = marked, and 5 = severe. A negative change from baseline indicates improvement.

    Time frame: Baseline, 2, 4, 8, 12, and 16 weeks

  10. Change From Baseline in PhGAP at Weeks 18, 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

    The PhGAP is used to determine the participant's psoriasis lesions overall at a given time point. The participant's psoriasis disease activity is assessed by a physician according to the grades of induration, erythema, and scaling on a scale of 0 to 5. The sum of the three grades is used to obtain the total average score. PhGAP is based on the total average score on a scale of 0-5 where, 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate, 4 = marked, and 5 = severe. A negative change from baseline indicates improvement.

    Time frame: Baseline, 18, 20, 24, 28, 36, and 48 weeks

  11. Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) at Weeks 4, 8, 12, and 16 in Participants With Psoriatic Nail Involvement at Baseline

    mNAPSI is used to assess each nail abnormality for each of the participant's nails. Three features or groups of features (pitting, onycholysis together with oil-drop dyschromia, and crumbling) of each fingernail are graded on a scale from 0 (no onycholysis together with oil-drop dyschromia, no pitting, no crumbling) to 3 (\>30 onycholysis together with oil-drop dyschromia, \>50 pitting, \>50% crumbling). Four features (leukonychia, splinter, hemorrhages, hyperkeratosis, and red spots in the lunula) are graded with the score of 1 = present or 0 = absent for each fingernail. Each finger has a score between 0 and 13. The total mNAPSI score is the sum of all abnormalities individual score across all fingers, and the total mNAPSI score ranges from 0 to 130. Lower numbers indicate fewer nail abnormalities. A negative change from baseline indicates improvement.

    Time frame: Baseline, 4, 8, 12, and 16 weeks

  12. Change From Baseline in mNAPSI at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriatic Nail Involvement at Baseline

    mNAPSI is used to assess each nail abnormality for each of the participant's nails. Three features or groups of features (pitting, onycholysis together with oil-drop dyschromia, and crumbling) of each fingernail are graded on a scale from 0 (no onycholysis together with oil-drop dyschromia, no pitting, no crumbling) to 3 (\>30 onycholysis together with oil-drop dyschromia, \>50 pitting, \>50% crumbling). Four features (leukonychia, splinter, hemorrhages, hyperkeratosis, and red spots in the lunula) are graded with the score of 1 = present or 0 = absent for each fingernail. Each finger has a score between 0 and 13. The total mNAPSI score is the sum of all abnormalities individual score across all fingers, and the total mNAPSI score ranges from 0 to 130. Lower numbers indicate fewer nail abnormalities. A negative change from baseline indicates improvement.

    Time frame: Baseline, 20, 24, 28, 36, and 48 weeks

  13. Change From Baseline in Leeds Enthesitis Index (LEI) at Weeks 4, 8, 12, and 16 in Participants With Enthesitis at Baseline

    Enthesitis is assessed using LEI. The enthesitis examination by LEI evaluates the presence or absence of pain by applying local pressure on 6 anatomical sites: medial femoral condyle (left and right), lateral epicondyle (left and right), and the achilles tendon insertion (left and right). Enthesitis at each site is scored as 0 (enthesitis absent) and 1 (enthesitis present). LEI is derived as the sum of the enthesitis score over the 6 sites mentioned above. The total score ranges from 0 to 6, higher scores indicates greater degree of enthesitis. A negative change from baseline indicates improvement.

    Time frame: Baseline, 4, 8, 12, and 16 weeks

  14. Change From Baseline in LEI at Weeks 20, 24, 28, 36, and 48 in Participants With Enthesitis at Baseline

    Enthesitis is assessed using LEI. The enthesitis examination by LEI evaluates the presence or absence of pain by applying local pressure on 6 anatomical sites: medial femoral condyle (left and right), lateral epicondyle (left and right), and the achilles tendon insertion (left and right). Enthesitis at each site is scored as 0 (enthesitis absent) and 1 (enthesitis present). LEI is derived as the sum of the enthesitis score over the 6 sites mentioned above. The total score ranges from 0 to 6, higher scores indicates greater degree of enthesitis. A negative change from baseline indicates improvement.

    Time frame: Baseline, 20, 24, 28, 36, and 48 weeks

  15. Change From Baseline in 12-Item Psoriatic Arthritis Impact of Disease (PsAID-12) Score at Weeks 4 and 16

    The PsAID questionnaire assesses the impact of PsA on people's lives. The PsAID is calculated based on 12 numerical rating scales (NRS) questions. The 12 NRS is focused on pain, fatigue, skin, work and/or leisure activities, function, discomfort, sleep, coping, anxiety, embarrassment, social life, and depression. Each NRS is assessed as a number between 0 and 10. Total score is calculated as the sum of the individual scores, (some of which were multiplied by a weighting factor) divided by 20 for a total possible score of 0 to 10, where higher score indicates worse impact of disease. A negative change from baseline indicates improvement.

    Time frame: Baseline, 4, and 16 weeks

  16. Change From Baseline in PsAID-12 Score at Week 48

    The PsAID questionnaire assesses the impact of PsA on people's lives. The PsAID is calculated based on 12 numerical rating scales (NRS) questions. The 12 NRS is focused on pain, fatigue, skin, work and/or leisure activities, function, discomfort, sleep, coping, anxiety, embarrassment, social life, and depression. Each NRS is assessed as a number between 0 and 10. Total score is calculated as the sum of the individual scores, (some of which were multiplied by a weighting factor) divided by 20 for a total possible score of 0 to 10, where higher score indicates worse impact of disease. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 48

  17. Percentage of Participants With PASDAS Low Disease Activity (LDA) at Weeks 4 and 16

    PASDAS is a composite disease activity measure for psoriatic arthritis. The PASDAS includes the following components: PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\]; PhGADA \[using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity)\]; 36-item short form survey (SF-36) \[a questionnaire which measures quality of life across eight domains used to determine a PCS with a score range of 0-100, higher scores indicates better health status\]; TJC68; SJC66; LEI \[assessed at 6 sites with a score range of 0 to 6, higher scores indicates higher degree of enthesitis\]; TDC \[with a score range of 0 to 60, higher score indicates higher degree of dactylitis\]; CRP. The score of PASDAS ranges from 0-10, lower score indicates better function. PASDAS LDA is defined as PASDAS ≤ 3.2.

    Time frame: Weeks 4 and 16

  18. Percentage of Participants With PASDAS LDA at Week 48

    PASDAS is a composite disease activity measure for psoriatic arthritis. The PASDAS includes the following components: PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\]; PhGADA \[using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity)\]; 36-item short form survey (SF-36) \[a questionnaire which measures quality of life across eight domains used to determine a PCS with a score range of 0-100, higher scores indicates better health status\]; TJC68; SJC66; LEI \[assessed at 6 sites with a score range of 0 to 6, higher scores indicates higher degree of enthesitis\]; TDC \[with a score range of 0 to 60, higher score indicates higher degree of dactylitis\]; CRP. The score of PASDAS ranges from 0-10, lower score indicates better function. PASDAS LDA is defined as PASDAS ≤ 3.2.

    Time frame: Week 48

  19. Percentage of Participants Who Achieved PASDAS Remission at Weeks 4 and 16

    PASDAS is a composite disease activity measure for psoriatic arthritis. The PASDAS includes the following components: PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\]; PhGADA \[using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity)\]; 36-item short form survey (SF-36) \[a questionnaire which measures quality of life across eight domains used to determine a PCS with a score range of 0-100, higher scores indicates better health status\]; TJC68; SJC66; LEI \[assessed at 6 sites with a score range of 0 to 6, higher scores indicates higher degree of enthesitis\]; TDC \[with a score range of 0 to 60, higher score indicates higher degree of dactylitis\]; CRP. The score of PASDAS ranges from 0-10, lower score indicates better function. PASDAS remission is defined as PASDAS ≤ 1.9.

    Time frame: Weeks 4 and 16

  20. Percentage of Participants Who Achieved PASDAS Remission at Week 48

    PASDAS is a composite disease activity measure for psoriatic arthritis. The PASDAS includes the following components: PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\]; PhGADA \[using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity)\]; 36-item short form survey (SF-36) \[a questionnaire which measures quality of life across eight domains used to determine a PCS with a score range of 0-100, higher scores indicates better health status\]; TJC68; SJC66; LEI \[assessed at 6 sites with a score range of 0 to 6, higher scores indicates higher degree of enthesitis\]; TDC \[with a score range of 0 to 60, higher score indicates higher degree of dactylitis\]; CRP. The score of PASDAS ranges from 0-10, lower score indicates better function. PASDAS remission is defined as PASDAS ≤ 1.9.

    Time frame: Week 48

  21. Percentage of Participants Who Achieved an American College of Rheumatology 20% Improvement Response at Weeks 2, 4, 8, 12, and 16

    ACR20 response is achieved when the participant has: ≥ 20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGADA using a VAS on a scale of 0 (very well) to 100 (very poor); PHGADA using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity); HAQ-DI inclusive of activities scored on a scale of 0 (no disability) to 3 (completely disabled); HAQ-DI pain assessment using VAS on a scale of 0 (no pain) to 100 (serious pain); and hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 2, 4, 8, 12, and 16

  22. Percentage of Participants Who Achieved an American College of Rheumatology 20% Improvement Response at Weeks 18, 20, 24, 28, 36, 48, and 60

    ACR20 response is achieved when the participant has: ≥ 20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGADA using a VAS on a scale of 0 (very well) to 100 (very poor); PHGADA using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity); HAQ-DI inclusive of activities scored on a scale of 0 (no disability) to 3 (completely disabled); HAQ-DI pain assessment using VAS on a scale of 0 (no pain) to 100 (serious pain); and hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 18, 20, 24, 28, 36, 48, and 60

  23. Percentage of Participants Who Achieve an American College of Rheumatology 50% Improvement Response at Weeks 2, 4, 8, 12, and 16

    ACR50 response is achieved when the participant has: ≥ 50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGADA using a VAS on a scale of 0 (very well) to 100 (very poor); PHGADA using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity); HAQ-DI inclusive of activities scored on a scale of 0 (no disability) to 3 (completely disabled); HAQ-DI pain assessment using VAS on a scale of 0 (no pain) to 100 (serious pain); and hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 2, 4, 8, 12, and 16

  24. Percentage of Participants Who Achieve an American College of Rheumatology 50% Improvement Response at Weeks 18, 20, 24, 28, 36, 48, and 60

    ACR50 response is achieved when the participant has: ≥ 50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGADA using a VAS on a scale of 0 (very well) to 100 (very poor); PHGADA using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity); HAQ-DI inclusive of activities scored on a scale of 0 (no disability) to 3 (completely disabled); HAQ-DI pain assessment using VAS on a scale of 0 (no pain) to 100 (serious pain); and hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 18, 20, 24, 28, 36, 48, and 60

  25. Percentage of Participants Who Achieve an American College of Rheumatology 70% Improvement Response at Weeks 2, 4, 8, 12, and 16

    ACR70 response is achieved when the participant has: ≥ 70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGADA using a VAS on a scale of 0 (very well) to 100 (very poor); PHGADA using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity); HAQ-DI inclusive of activities scored on a scale of 0 (no disability) to 3 (completely disabled); HAQ-DI pain assessment using VAS on a scale of 0 (no pain) to 100 (serious pain); and hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 2, 4, 8, 12, and 16

  26. Percentage of Participants Who Achieve an American College of Rheumatology 70% Improvement Response at Weeks 18, 20, 24, 28, 36, 48, and 60

    ACR70 response is achieved when the participant has: ≥ 70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGADA using a VAS on a scale of 0 (very well) to 100 (very poor); PHGADA using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity); HAQ-DI inclusive of activities scored on a scale of 0 (no disability) to 3 (completely disabled); HAQ-DI pain assessment using VAS on a scale of 0 (no pain) to 100 (serious pain); and hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 18, 20, 24, 28, 36, 48, and 60

  27. Change From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 2, 4, 8, 12, and 16

    TJC68 is an assessment of 68 joints. Each joint is evaluated as 'normal', 'tender', 'tender and swollen', or 'not able to evaluate'. It is derived as the sum of all tender joints. The overall tender joint count ranged from 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline indicates improvement.

    Time frame: Baseline, 2, 4, 8, 12, and 16 weeks

  28. Change From Baseline in Individual ACR Component: TJC68 at Weeks 18, 20, 24, 28, 36, 48, and 60

    TJC68 is an assessment of 68 joints. Each joint is evaluated as 'normal', 'tender', 'tender and swollen', or 'not able to evaluate'. It is derived as the sum of all tender joints. The overall tender joint count ranged from 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline indicates improvement.

    Time frame: Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks

  29. Change From Baseline in ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 2, 4, 8, 12, and 16

    SJC66 is an assessment of 66 joints. Each joint was evaluated as 'normal', 'swollen', 'tender and swollen', or 'not able to evaluate'. It is derived as the sum of all swollen joints. The overall swollen joint count ranged from 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline indicates improvement.

    Time frame: Baseline, 2, 4, 8, 12, and 16 weeks

  30. Change From Baseline in ACR Component: SJC66 at Weeks 18, 20, 24, 28, 36, 48, and 60

    SJC66 is an assessment of 66 joints. Each joint was evaluated as 'normal', 'swollen', 'tender and swollen', or 'not able to evaluate'. It is derived as the sum of all swollen joints. The overall swollen joint count ranged from 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline indicates improvement.

    Time frame: Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks

  31. Change From Baseline in Individual ACR Component: Patient's Global Assessment of Disease Activity (PGADA) at Weeks 2, 4, 8, 12, and 16

    PGADA is assessed by the participants using a VAS on a scale of 0 (very well) to 100 (very poor). A negative change from baseline indicates improvement.

    Time frame: Baseline, 2, 4, 8, 12, and 16 weeks

  32. Change From Baseline in Individual ACR Component: PGADA at Weeks 18, 20, 24, 28, 36, 48, and 60

    PGADA is assessed by the participants using a VAS on a scale of 0 (very well) to 100 (very poor). A negative change from baseline indicates improvement.

    Time frame: Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks

  33. Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PhGADA) at Weeks 2, 4, 8, 12, and 16

    PhGADA is assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

    Time frame: Baseline, 2, 4, 8, 12, and 16 weeks

  34. Change From Baseline in Individual ACR Component: PhGADA at Weeks 18, 20, 24, 28, 36, 48, and 60

    PhGADA is assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

    Time frame: Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks

  35. Change From Baseline in Individual ACR Component: Health Assessment Questionnaire Disability Index (HAQ-DI)'s Pain Assessment at Weeks 2, 4, 8, 12, and 16

    HAQ-DI's pain assessment is done using VAS on a scale of 0 (no pain) to 100 (serious pain). A negative change from baseline indicates improvement.

    Time frame: Baseline, 2, 4, 8, 12, and 16 weeks

  36. Change From Baseline in Individual ACR Component: Health Assessment Questionnaire Disability Index (HAQ-DI)'s Pain Assessment at Weeks 18, 20, 24, 28, 36, 48, and 60

    HAQ-DI's pain assessment is done using VAS on a scale of 0 (no pain) to 100 (serious pain). A negative change from baseline indicates improvement.

    Time frame: Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks

  37. Change From Baseline in Individual ACR Component: High-Sensitivity C- Reactive Protein (hsCRP) at Weeks 2, 4, 8, 12, and 16

    The hsCRP is the ACR core set measure of acute phase reactant. It was measured at the central laboratory to help assess the effect of filgotinib on the participant's psoriatic arthritis. A negative change from baseline indicates improvement.

    Time frame: Baseline, 2, 4, 8, 12, and 16 weeks

  38. Change From Baseline in Individual ACR Component: hsCRP at Weeks 18, 20, 24, 28, 36, 48, and 60

    The hsCRP is the ACR core set measure of acute phase reactant. It was measured at the central laboratory to help assess the effect of filgotinib on the participant's psoriatic arthritis. A negative change from baseline indicates improvement.

    Time frame: Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks

  39. Change From Baseline in Disease Activity Score 28 (DAS28) C-Reactive Protein (CRP) at Weeks 2, 4, 8, 12, and 16

    The DAS28(CRP) is a measure of the participant's disease activity calculated using the tender joint count (28 joints), swollen joint count (28 joints), PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\] and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

    Time frame: Baseline, 2, 4, 8, 12, and 16 weeks

  40. Change From Baseline in DAS28(CRP) at Weeks 18, 20, 24, 28, 36, 48 and 60

    The DAS28(CRP) is a measure of the participant's disease activity calculated using the tender joint count (28 joints), swollen joint count (28 joints), PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\] and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

    Time frame: Baseline, 18, 20, 24, 28, 36, 48 and 60 weeks

  41. Percentage of Participants Who Achieved DAS28(CRP) LDA at Weeks 2, 4, 8, 12, and 16

    The DAS28 (CRP) is a measure of the participant's disease activity calculated using the tender joint count (28 joints), swollen joint count (28 joints), PGADA (VAS; 0 = very well to 100 = very poor), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. DAS28 (CRP) LDA is defined as DAS28(CRP) ≤ 3.2.

    Time frame: Weeks 2, 4, 8, 12, and 16

  42. Percentage of Participants Who Achieved DAS28(CRP) LDA at Weeks 18, 20, 24, 28, 36, 48, and 60

    The DAS28 (CRP) is a measure of the participant's disease activity calculated using the tender joint count (28 joints), swollen joint count (28 joints), PGADA (VAS; 0 = very well to 100 = very poor), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. DAS28 (CRP) LDA is defined as DAS28(CRP) ≤ 3.2.

    Time frame: Weeks 18, 20, 24, 28, 36, 48, and 60

  43. Percentage of Participants Who Achieved DAS28(CRP) Remission at Weeks 2, 4, 8, 12, and 16

    The DAS28 (CRP) is a measure of the participant's disease activity calculated using the tender joint count (28 joints), swollen joint count (28 joints), PGADA (VAS; 0 = very well to 100 = very poor), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. DAS28 (CRP) remission is defined as DAS28 (CRP) \< 2.6.

    Time frame: Weeks 2, 4, 8, 12, and 16

  44. Percentage of Participants Who Achieved DAS28(CRP) Remission at Weeks 18, 20, 24, 28, 36, 48, and 60

    The DAS28 (CRP) is a measure of the participant's disease activity calculated using the tender joint count (28 joints), swollen joint count (28 joints), PGADA (VAS; 0 = very well to 100 = very poor), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. DAS28 (CRP) remission is defined as DAS28 (CRP) \< 2.6.

    Time frame: Weeks 18, 20, 24, 28, 36, 48, and 60

  45. Time to Achieve DAS28(CRP) LDA

    The DAS28 (CRP) is a measure of the participant's disease activity calculated using the TJC (28 joints), SJC (28 joints), PGADA (VAS; 0 = very well to 100 = very poor), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. DAS28 (CRP) LDA is defined as DAS28 (CRP) ≤ 3.2. Time to achieve DAS28(CRP) LDA is the number of days from the first dose date of study drug administration to the first time when a participant achieves DAS28(CRP) LDA.

    Time frame: Approximately 16 weeks

  46. Percentage of Participants Who Achieved DAPSA LDA at Weeks 2, 4, 8, 12, and 16

    DAPSA is calculated by summing the following components: TJC68; SJC66; PGADA \[using VAS on a scale of 0 (very well) to 100 very poor)\]; PGAPI \[using a VAS on a scale of 0 (no pain) to 100 (serious pain)\] and CRP. DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. DAPSA LDA is defined as DAPSA ≤ 14.

    Time frame: Weeks 2, 4, 8, 12, and 16

  47. Percentage of Participants Who Achieved DAPSA LDA at Weeks 18, 20, 24, 28, 36, 48, and 60

    DAPSA is calculated by summing the following components: TJC68; SJC66; PGADA \[using VAS on a scale of 0 (very well) to 100 very poor)\]; PGAPI \[using a VAS on a scale of 0 (no pain) to 100 (serious pain)\] and CRP. DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. DAPSA LDA is defined as DAPSA ≤ 14.

    Time frame: Weeks 18, 20, 24, 28, 36, 48, and 60

  48. Percentage of Participants Who Achieved DAPSA Remission at Weeks 2, 4, 8, 12, and 16

    DAPSA is calculated by summing the following components: TJC68; SJC66; PGADA \[using VAS on a scale of 0 (very well) to 100 very poor)\]; PGAPI \[using a VAS on a scale of 0 (no pain) to 100 (serious pain)\] and CRP. DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. DAPSA remission is defined as DAPSA ≤ 4.

    Time frame: Weeks 2, 4, 8, 12, and 16

  49. Percentage of Participants Who Achieved DAPSA Remission at Weeks 18, 20, 24, 28, 36, 48, and 60

    DAPSA is calculated by summing the following components: TJC68; SJC66; PGADA \[using VAS on a scale of 0 (very well) to 100 very poor)\]; PGAPI \[using a VAS on a scale of 0 (no pain) to 100 (serious pain)\] and CRP. DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. DAPSA remission is defined as DAPSA ≤ 4.

    Time frame: Weeks 18, 20, 24, 28, 36, 48, and 60

  50. Time to Achieve DAPSA LDA

    DAPSA is calculated by summing the following components: TJC68; SJC66; PGADA \[using VAS on a scale of 0 (very well) to 100 very poor)\]; PGAPI \[using a VAS on a scale of 0 (no pain) to 100 (serious pain)\] and CRP. DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. DAPSA LDA is defined as DAPSA ≤ 14. Time to achieve DAPSA LDA is the number of days from the first dose date of study drug administration to the first time when a participant achieves DAPSA LDA. If the DAPSA LDA is not achieved during main study phase, the time to achieve DAPSA LDA will be censored at the last non-missing DAPSA LDA assessment date during main study phase. If the component scores of DAPSA LDA are at different dates for a visit, the latest date will be used for the derivation of time to achieve DAPSA LDA.

    Time frame: Approximately 16 weeks

  51. Percentage of Participants Who Achieved Psoriatic Arthritis Response Criteria (PsARC) Response at Weeks 2, 4, 8, 12, and 16

    The PsARC response was defined as improvement in at least 2 of the following 4 criteria; ≥ 30% decrease in SJC66, ≥ 30% decrease in TJC68, ≥ 20% decrease in PGADA (VAS; 0 = very well to 100 = very poor), ≥ 20% decrease in PhGADA (VAS; 0 = no disease activity to 100 = maximum disease activity) and with at least one of the 2 joint criteria, with no deterioration in any other criteria.

    Time frame: Weeks 2, 4, 8, 12, and 16

  52. Percentage of Participants Who Achieved PsARC Response at Weeks 18, 20, 24, 28, 36, 48, and 60

    The PsARC response was defined as improvement in at least 2 of the following 4 criteria; ≥ 30% decrease in SJC66, ≥ 30% decrease in TJC68, ≥ 20% decrease in PGADA (VAS; 0 = very well to 100 = very poor), ≥ 20% decrease in PhGADA (VAS; 0 = no disease activity to 100 = maximum disease activity) and with at least one of the 2 joint criteria, with no deterioration in any other criteria.

    Time frame: Weeks 18, 20, 24, 28, 36, 48, and 60

  53. Change From Baseline in Psoriasis Area and Severity Index (PASI) at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

    PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, where 0 = none, 1 = mild, 2 = moderate, 3 = severe and 4 = very severe, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). A higher score indicates more severe disease. A negative change from baseline indicates improvement.

    Time frame: Baseline, 4, 8, 12, and 16 weeks

  54. Change From Baseline in Psoriasis Area and Severity Index (PASI) at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

    PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, where 0 = none, 1 = mild, 2 = moderate, 3 = severe and 4 = very severe, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). A higher score indicates more severe disease. A negative change from baseline indicates improvement.

    Time frame: Baseline, 20, 24, 28, 36, and 48 weeks

  55. Percentage of Participants Who Achieved Psoriasis Area and Severity Index 50% Improvement (PASI50) Response at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

    PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI50, the improvement threshold from baseline in PASI score is 50%. A higher score indicates more severe disease.

    Time frame: Weeks 4, 8, 12, and 16

  56. Percentage of Participants Who Achieved PASI50 Response at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

    PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI50, the improvement threshold from baseline in PASI score is 50%. A higher score indicates more severe disease.

    Time frame: Weeks 20, 24, 28, 36, and 48

  57. Percentage of Participants Who Achieved Psoriasis Area and Severity Index 75% Improvement (PASI75) Response at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

    PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI75, the improvement threshold from baseline in PASI score is 75%. A higher score indicates more severe disease.

    Time frame: Weeks 4, 8, 12, and 16

  58. Percentage of Participants Who Achieved PASI75 Response at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

    PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI75, the improvement threshold from baseline in PASI score is 75%. A higher score indicates more severe disease.

    Time frame: Weeks 20, 24, 28, 36, and 48

  59. Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90% Improvement (PASI90) Response at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

    PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI90, the improvement threshold from baseline in PASI score is 90%. A higher score indicates more severe disease.

    Time frame: Weeks 4, 8, 12, and 16

  60. Percentage of Participants Who Achieved PASI90 Response at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

    PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI90, the improvement threshold from baseline in PASI score is 90%. A higher score indicates more severe disease.

    Time frame: Weeks 20, 24, 28, 36, and 48

  61. Percentage of Participants Who Achieved Psoriasis Area and Severity Index 100% Improvement (PASI100) Response at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

    PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI100, the improvement threshold from baseline in PASI score is 100%. A higher score indicates more severe disease.

    Time frame: Weeks 4, 8, 12, and 16

  62. Percentage of Participants Who Achieved PASI100 Response at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

    PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI100, the improvement threshold from baseline in PASI score is 100%. A higher score indicates more severe disease.

    Time frame: Weeks 20, 24, 28, 36, and 48

  63. Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index at Weeks 4, 8, 12, and 16 in Participants With Enthesitis at Baseline

    The enthesitis examination is based on the 16 anatomical sites: the medial epicondyle (left and right), the lateral epicondyle (left and right), the supraspinatus insertion (left and right), the bilateral greater trochanter (left and right), the quadriceps tendon insertion into superior border of patella (left and right), the patellar ligament insertion into inferior pole of patella or tibial tuberosity (left and right), the achilles tendon insertion (left and right), and the plantar fascia insertion (left and right). Enthesitis at each site is scored as either 0 (enthesitis absent) and 1 (enthesitis present). SPARCC enthesitis index has an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis. A negative change from baseline indicates improvement.

    Time frame: Baseline, 4, 8, 12, and 16 weeks

  64. Change From Baseline in SPARCC Enthesitis Index at Weeks 20, 24, 28, 36, and 48 in Participants With Enthesitis at Baseline

    The enthesitis examination is based on the 16 anatomical sites: the medial epicondyle (left and right), the lateral epicondyle (left and right), the supraspinatus insertion (left and right), the bilateral greater trochanter (left and right), the quadriceps tendon insertion into superior border of patella (left and right), the patellar ligament insertion into inferior pole of patella or tibial tuberosity (left and right), the achilles tendon insertion (left and right), and the plantar fascia insertion (left and right). Enthesitis at each site is scored as either 0 (enthesitis absent) and 1 (enthesitis present). SPARCC enthesitis index has an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis. A negative change from baseline indicates improvement.

    Time frame: Baseline, 20, 24, 28, 36, and 48 weeks

  65. Change From Baseline in Leeds Dactylitis Index (LDI) at Weeks 4, 8, 12, and 16 in Participants With Dactylitis at Baseline

    LDI quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with an at least 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, values from a standard reference table. LDI measures the ratio of the circumference of affected digit to circumference of digit on contralateral hand or foot using a Leeds Dactylometer. LDI score is calculated based on circumference of the dactylitic finger/toe (mm), circumference of the contralateral digit (mm), tenderness score (0 = no tenderness, 1 = tender). Tenderness of affected digits is assessed on a scale from 0 (no tenderness) to 3 (tender and withdrawn). A higher LDI indicates worse dactylitis. Negative change from baseline indicates improvement.

    Time frame: Baseline, 4, 8, 12, and 16 weeks

  66. Change From Baseline in LDI at Weeks 20, 24, 28, 36, and 48 in Participants With Dactylitis at Baseline

    LDI quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with an at least 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, values from a standard reference table. LDI measures the ratio of the circumference of affected digit to circumference of digit on contralateral hand or foot using a Leeds Dactylometer. LDI score is calculated based on the circumference of the dactylitic finger/toe (mm), circumference of contralateral digit (mm), tenderness score (0 = no tenderness, 1 = tender). Tenderness of affected digits is assessed on a scale from 0 (no tenderness) to 3 (tender and withdrawn). A higher LDI indicates worse dactylitis. Negative change from baseline indicates improvement.

    Time frame: Baseline, 20, 24, 28, 36, and 48 weeks

  67. Change From Baseline in Tender Dactylitis Count (TDC) at Weeks 4, 8, 12, and 16 in Participants With Dactylitis at Baseline

    Tender score (0 = no tenderness, 1 = tender, 2 = tender and wince, 3 = tender and withdraw) is collected for Dactylitis Assessments on the Dactylitis Score Sheet that is used for calculation of LDI total score. Tender dactylitis count (TDC) equals the number of tender fingers and toes (tendor score \>0). For participants with dactylitis status absent for all the fingers and toes, the TDC is set as 0. The total score range of TDC is from 0 to 60, higher scores indicate greater presence of dactylitis. A negative change from baseline indicates improvement.

    Time frame: Baseline, 4, 8, 12, and 16 weeks

  68. Change From Baseline in TDC at Weeks 20, 24, 28, 36, and 48 in Participants With Dactylitis at Baseline

    Tender score (0 = no tenderness, 1 = tender, 2 = tender and wince, 3 = tender and withdraw) is collected for Dactylitis Assessments on the Dactylitis Score Sheet that is used for calculation of LDI total score. Tender dactylitis count (TDC) equals the number of tender fingers and toes (tendor score \>0). For participants with dactylitis status absent for all the fingers and toes, the TDC is set as 0. The total score range of TDC is from 0 to 60, higher scores indicate greater presence of dactylitis. A negative change from baseline indicates improvement.

    Time frame: Baseline, 20, 24, 28, 36, and 48 weeks

  69. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Weeks 2, 4, 8, 12, and 16

    The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). When 6 or more categories are non-missing, total possible score is 3. If more than 2 categories are missing, the HAQ-DI score is set to missing. A negative change from baseline indicates improvement (less disability).

    Time frame: Baseline, 2, 4, 8, 12, and 16 weeks

  70. Change From Baseline in HAQ-DI Score at Weeks 18, 20, 24, 28, 36, 48, and 60

    The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). When 6 or more categories are non-missing, total possible score is 3. If more than 2 categories are missing, the HAQ-DI score is set to missing. A negative change from baseline indicates improvement (less disability).

    Time frame: Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks

  71. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue) Score at Weeks 4 and 16

    FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Higher scores indicate less fatigue. Positive change in value indicates improvement (no or less severity of fatigue).

    Time frame: Baseline, 4, and 16 weeks

  72. Change From Baseline in FACIT-Fatigue Scale Score at Week 48

    FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Higher scores indicate better quality of life. Positive change in value indicates improvement (no or less severity of fatigue).

    Time frame: Baseline, Week 48

  73. Change From Baseline in Mental Component Score (MCS) of the 36-Item Short-Form Version 2 (SF-36v2) at Weeks 4 and 16

    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consists of social functioning, vitality, mental health, and role-emotional scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. A positive change from baseline indicated improvement (better health status).

    Time frame: Baseline, 4, and 16 weeks

  74. Change From Baseline in MCS of the SF-36v2 at Week 48

    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consists of social functioning, vitality, mental health, and role-emotional scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. A positive change from baseline indicated improvement (better health status).

    Time frame: Baseline, Week 48

  75. Change From Baseline in Physical Component Score (PCS) of the SF-36v2 at Weeks 4 and 16

    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). PCS consists of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. A positive change from baseline indicates improvement (better health status).

    Time frame: Baseline, 4, and 16 weeks

  76. Change From Baseline in PCS of the SF-36v2 at Week 48

    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). PCS consists of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. A positive change from baseline indicates improvement (better health status).

    Time frame: Baseline, Week 48

07

Results

Posted Mar 18, 2022

Participant flow

Participants were enrolled at study sites in the United States, Europe, Canada, Australia, and Asia. The first participant was screened on 13 November 2019. The last study visit occurred on 18 March 2021.

Main Study (Up to 16 Weeks)
Participant flow — Main Study (Up to 16 Weeks)
MilestoneFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)Filgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Started3634360000
Completed1820180000
Not completed1814180000
Withdrew: Study terminated by sponsor1413140000
Withdrew: Withdrew consent2130000
Withdrew: Adverse event2000000
Withdrew: Investigator's discretion0010000
LTE Phase (After Week 16 to Week 63)
Participant flow — LTE Phase (After Week 16 to Week 63)
MilestoneFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)Filgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Started0001820108
Completed0000000
Not completed0001820108
Withdrew: Study terminated by sponsor0001719108
Withdrew: Adverse event0001100

Outcome measures

PrimaryPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement Response at Week 12

ACR20 response is achieved when the participant has: ≥ 20% improvement (reduction) from baseline in tender joint count based on 68 joints (TJC68), swollen joint count based on 66 joints (SJC66) and in at least 3 of the following 5 items: patient's global assessment of disease activity (PGADA) using a visual analogue scale (VAS) on a scale of 0 (very well) to 100 (very poor); physician's global assessment of disease activity (PHGADA) using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity); health assessment questionnaire-disability index (HAQ-DI) inclusive of activities scored on a scale of 0 (no disability) to 3 (completely disabled); HAQ-DI pain assessment using VAS on a scale of 0 (no pain) to 100 (serious pain), and high-sensitivity C-reactive protein (hsCRP).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement Response at Week 12
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement Response at Week 1260.0 (43.5 to 76.5)35.3 (17.8 to 52.8)33.1 (17.0 to 49.1)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Multiple imputation method · p = 0.022 (The stratification factors (Geographic Region, Concurrent Use of conventional synthetic (cs) DMARD(s) and/or Apremilast at Randomization, Prior Use of biologic (bio)DMARD(s)) and treatment groups were included in the imputation model as covariates.) · Difference in response rates: 26.9 · 95% CI 4.3 to 49.6
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Multiple imputation method · p = 0.89 (The stratification factors (Geographic Region, Concurrent Use of csDMARD(s) and/or Apremilast at Randomization, Prior Use of bioDMARD(s)) and treatment groups were included in the imputation model as covariates.) · Difference in response rates: 2.2 · 95% CI -20.5 to 25.0
SecondaryChange From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 4 and 16

PASDAS is a composite disease activity measure for psoriatic arthritis. The PASDAS includes the following components: PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\]; PhGADA \[using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity)\]; 36-item short form survey (SF-36) \[a questionnaire which measures quality of life across eight domains used to determine a physical component summary (PCS) with a score range of 0-100, higher scores indicates better health status\]; TJC68; SJC66; leeds enthesitis index (LEI) \[assessed at 6 sites with a score range of 0 to 6, higher scores indicates higher degree of enthesitis\]; Tender dactylitis count (TDC) \[with a score range of 0 to 60, higher score indicates higher degree of dactylitis\]; C-reactive protein (CRP). The score of PASDAS ranges from 0-10, lower scores indicates better function. A negative change from baseline indicates improvement.

Time frame:
Baseline, 4, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 4 and 16
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 4-1.2 ± 1.34-0.8 ± 0.73-0.6 ± 0.96
Change from Baseline at Week 16-2.1 ± 1.73-1.4 ± 1.19-0.9 ± 1.08
SecondaryChange From Baseline in PASDAS at Week 48

PASDAS is a composite disease activity measure for psoriatic arthritis. The PASDAS includes the following components: PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\]; PhGADA \[using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity)\]; 36-item short form survey (SF-36) \[a questionnaire which measures quality of life across eight domains used to determine a physical component summary (PCS) with a score range of 0-100, higher scores indicates better health status\]; TJC68; SJC66; leeds enthesitis index (LEI) \[assessed at 6 sites with a score range of 0 to 6, higher scores indicates higher degree of enthesitis\]; Tender dactylitis count (TDC) \[with a score range of 0 to 60, higher score indicates higher degree of dactylitis\]; C-reactive protein (CRP). The score of PASDAS ranges from 0-10, lower scores indicates better function. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 48
Reported as:
Mean · score on a scale
Change From Baseline in PASDAS at Week 48
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change From Baseline in PASDAS at Week 48-3.3 ± 1.69-2.0 ± 1.35-1.7 ± 0.570.0 ± 0.30
SecondaryPercentage of Participants Who Achieved Minimal Disease Activity (MDA) Response at Weeks 4, 8, 12, and 16

MDA is a measure to indicate disease remission, and is based on a composite score of 7 domains. A participant is considered as having achieved the MDA if the participant fulfills at least 5 of the following 7 criteria: TJC68 ≤1; SJC66 ≤1; Psoriatic arthritis disease activity score (PASI) ≤1 for participants with psoriasis covering BSA \<3% \[PASI evaluates the severity and extent of psoriasis. In PASI, body is divided into four parts, head and neck, upper limb, trunk and lower limbs. Each area is assessed for erythema, induration and scaling, each rated on a scale of 0 to 4. The total score ranges from 0 (no disease) to 72 (maximal disease)\]; PGAPI ≤15 \[using VAS on a scale of 0 (no pain) to 100 (serious pain)\]; PGADA ≤20 \[using VAS on a scale of 0 (very well) to 100 (very poor)\]; HAQ-DI score ≤0.5; LEI score ≤1 for participants with enthesitis at baseline.

Time frame:
Weeks 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) Response at Weeks 4, 8, 12, and 16
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 45.6 (0.0 to 14.4)8.8 (0.0 to 19.8)11.4 (0.0 to 23.4)
Week 815.6 (1.5 to 29.8)11.8 (0.0 to 24.1)14.7 (1.3 to 28.1)
Week 1221.2 (5.7 to 36.7)17.6 (3.4 to 31.9)8.8 (0.0 to 19.8)
Week 1634.4 (16.4 to 52.4)24.2 (8.1 to 40.4)12.1 (0.0 to 24.8)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.39 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic Region, concurrent Use of csDMARD(s) and/or Apremilast at Randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: -5.9 · 95% CI -21.6 to 9.995% confidence interval (CI) for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.65 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic Region, concurrent Use of csDMARD(s) and/or Apremilast at Randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: -2.6 · 95% CI -19.7 to 14.595% confidence interval (CI) for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.86 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic Region, concurrent Use of csDMARD(s) and/or Apremilast at Randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 0.9 · -19.4% CI -19.4 to 21.395% confidence interval (CI) for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.70 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic Region, concurrent Use of csDMARD(s) and/or Apremilast at Randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: -2.9 · 95% CI -22.0 to 16.195% confidence interval (CI) for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.15 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic Region, concurrent Use of csDMARD(s) and/or Apremilast at Randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 12.4 · 95% CI -7.5 to 32.395% confidence interval (CI) for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.30 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic Region, concurrent Use of csDMARD(s) and/or Apremilast at Randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 8.8 · 95% CI -10.1 to 27.795% confidence interval (CI) for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.035 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic Region, concurrent Use of csDMARD(s) and/or Apremilast at Randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 22.3 · 95% CI -0.7 to 45.295% confidence interval (CI) for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.22 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic Region, concurrent Use of csDMARD(s) and/or Apremilast at Randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 12.1 · 95% CI -9.3 to 33.595% confidence interval (CI) for difference in response rates were based on normal approximation method with a continuity correction.
SecondaryPercentage of Participants Who Achieved MDA Response at Weeks 20, 24, 28, 36, and 48

MDA is a measure to indicate disease remission, and is based on a composite score of 7 domains. A participant is considered as having achieved the MDA if the participant fulfills at least 5 of the following 7 criteria: TJC68 ≤1; SJC66 ≤1; Psoriatic arthritis disease activity score (PASI) ≤1 for participants with psoriasis covering BSA \<3% \[PASI evaluates the severity and extent of psoriasis. In PASI, body is divided into four parts, head and neck, upper limb, trunk and lower limbs. Each area is assessed for erythema, induration and scaling, each rated on a scale of 0 to 4. The total score ranges from 0 (no disease) to 72 (maximal disease)\]; PGAPI ≤15 \[using VAS on a scale of 0 (no pain) to 100 (serious pain)\]; PGADA ≤20 \[using VAS on a scale of 0 (very well) to 100 (very poor)\]; HAQ-DI score ≤0.5; LEI score ≤1 for participants with enthesitis at baseline.

Time frame:
Weeks 20, 24, 28, 36, and 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved MDA Response at Weeks 20, 24, 28, 36, and 48
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Week 2030.8 (1.8 to 59.7)21.1 (0.1 to 42.0)40.0 (4.6 to 75.4)0 (0.0 to 6.3)
Week 2438.5 (8.2 to 68.8)43.8 (16.3 to 71.2)71.4 (30.8 to 100.0)28.6 (0.0 to 69.2)
Week 2837.5 (0.0 to 77.3)36.4 (3.4 to 69.3)50.0 (0.0 to 100.0)20.0 (0.0 to 65.1)
Week 3655.6 (17.5 to 93.6)30.0 (0.0 to 63.4)50.0 (0.0 to 100.0)20.0 (0.0 to 65.1)
Week 4862.5 (22.7 to 100.0)11.1 (0.0 to 37.2)75.0 (20.1 to 100.0)0 (0.0 to 16.7)
SecondaryPercentage of Participants Who Achieved Very Low Disease Activity (VLDA) Response at Weeks 4, 8, 12, and 16

VLDA is a measure to indicate disease remission, and is based on a composite score of 7 domains. A participant is considered as having achieved the VLDA if the participant fulfills all the seven criteria: TJC68 ≤1; SJC66 ≤1; PASI score ≤1 for participants with psoriasis covering BSA \<3% \[PASI evaluates the severity and extent of psoriasis. In PASI, body is divided into four parts, head and neck, upper limb, trunk and lower limbs. Each area is assessed for erythema, induration and scaling, each rated on a scale of 0 to 4. The total score ranges from 0 (no disease) to 72 (maximal disease)\]; PGAPI ≤15 \[using VAS on a scale of 0 (no pain) to (serious pain)\]; PGADA ≤20 \[using VAS on a scale of 0 (very well) to 100 (very poor)\]; HAQ-DI score ≤0.5; LEI score ≤1 with participants with enthesitis at baseline.

Time frame:
Weeks 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Very Low Disease Activity (VLDA) Response at Weeks 4, 8, 12, and 16
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 40 (0.0 to 1.4)0 (0.0 to 1.5)0 (0.0 to 1.4)
Week 83.1 (0.0 to 10.7)0 (0.0 to 1.5)0 (0.0 to 1.5)
Week 123.0 (0.0 to 10.4)5.9 (0.0 to 15.3)0 (0.0 to 1.5)
Week 163.1 (0.0 to 10.7)6.1 (0.0 to 15.7)3.0 (0.0 to 10.4)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.0 · 95% CI -2.8 to 2.895% CI for response rate and difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.0 · 95% CI -2.9 to 2.995% CI for response rate and difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 3.1 · 95% CI -5.9 to 12.295% CI for response rate and difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.0 · 95% CI -2.9 to 2.995% CI for response rate and difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 3.0 · 95% CI -5.8 to 11.995% CI for response rate and difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 5.9 · 95% CI -5.0 to 16.795% CI for response rate and difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.1 · 95% CI -11.4 to 11.695% CI for response rate and difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 3.0 · 95% CI -10.0 to 16.195% CI for response rate and difference in response rates were based on normal approximation method with a continuity correction.
SecondaryPercentage of Participants Who Achieved VLDA Response at Weeks 20, 24, 28, 36, and 48

VLDA is a measure to indicate disease remission, and is based on a composite score of 7 domains. A participant is considered as having achieved the VLDA if the participant fulfills all the seven criteria: TJC68 ≤1; SJC66 ≤1; PASI score ≤1 for participants with psoriasis covering BSA \<3% \[PASI evaluates the severity and extent of psoriasis. In PASI, body is divided into four parts, head and neck, upper limb, trunk and lower limbs. Each area is assessed for erythema, induration and scaling, each rated on a scale of 0 to 4. The total score ranges from 0 (no disease) to 72 (maximal disease)\]; PGAPI ≤15 \[using VAS on a scale of 0 (no pain) to (serious pain)\]; PGADA ≤20 \[using VAS on a scale of 0 (very well) to 100 (very poor)\]; HAQ-DI score ≤0.5; LEI score ≤1 with participants with enthesitis at baseline.

Time frame:
Weeks 20, 24, 28, 36, and 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved VLDA Response at Weeks 20, 24, 28, 36, and 48
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Week 207.7 (0.0 to 26.0)0 (0.0 to 2.6)10.0 (0.0 to 33.6)0 (0.0 to 6.3)
Week 247.7 (0.0 to 26.0)12.5 (0.0 to 31.8)14.3 (0.0 to 47.4)0 (0.0 to 7.1)
Week 2812.5 (0.0 to 41.7)0 (0.0 to 4.5)0 (0.0 to 12.5)0 (0.0 to 10.0)
Week 3622.2 (0.0 to 54.9)10.0 (0.0 to 33.6)0 (0.0 to 12.5)0 (0.0 to 10.0)
Week 480 (0.0 to 6.3)0 (0.0 to 5.6)0 (0.0 to 12.5)0 (0.0 to 16.7)
SecondaryChange From Baseline in Disease Activity in Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, and 16

DAPSA is calculated by summing the following components: TJC68; SJC66; PGADA \[using VAS on a scale of 0 (very well) to 100 very poor)\]; PGAPI \[using a VAS on a scale of 0 (no pain) to 100 (serious pain)\] and CRP. DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. A negative change from baseline indicates improvement.

Time frame:
Baseline, 2, 4, 8, 12, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Disease Activity in Psoriatic Arthritis (DAPSA) at Weeks 2, 4, 8, 12, and 16
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 2-11.6 ± 19.12-9.4 ± 14.11-2.9 ± 16.01
Change from Baseline at Week 4-15.1 ± 18.48-11.5 ± 12.53-8.0 ± 19.32
Change from Baseline at Week 8-22.0 ± 21.73-14.4 ± 14.96-14.4 ± 20.15
Change from Baseline at Week 12-25.2 ± 24.43-15.8 ± 19.32-14.9 ± 16.43
Change from Baseline at Week 16-26.3 ± 23.48-19.4 ± 18.13-16.6 ± 15.61
SecondaryChange From Baseline in DAPSA at Weeks 18, 20, 24, 28, 36, 48, and 60

DAPSA is calculated by summing the following components: TJC68; SJC66; PGADA \[using VAS on a scale of 0 (very well) to 100 very poor)\]; PGAPI \[using a VAS on a scale of 0 (no pain) to 100 (serious pain)\] and CRP. DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. A negative change from baseline indicates improvement.

Time frame:
Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks
Reported as:
Mean · score on a scale
Change From Baseline in DAPSA at Weeks 18, 20, 24, 28, 36, 48, and 60
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 18-27.0 ± 22.87-23.5 ± 18.80-9.3 ± 9.10-5.3 ± 9.72
Change from Baseline at Week 20-32.1 ± 29.72-20.5 ± 15.12-9.6 ± 11.791.1 ± 16.48
Change from Baseline at Week 24-28.8 ± 37.40-22.1 ± 18.37-6.9 ± 6.51-5.4 ± 15.02
Change from Baseline at Week 28-37.3 ± 26.49-24.1 ± 20.79-3.0 ± 7.61-5.3 ± 20.48
Change from Baseline at Week 36-44.9 ± 27.81-23.6 ± 18.30-1.3 ± 10.75-9.9 ± 13.51
Change from Baseline at Week 48-40.5 ± 31.97-28.5 ± 20.68-16.3 ± 21.00-2.3 ± 17.56
Change from Baseline at Week 60-86.2 ± NA-18.5 ± NA-12.9 ± 11.801.8 ± 23.75
SecondaryChange From Baseline in Physician's Global Assessment of Psoriasis (PhGAP) at Weeks 2, 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the Body Surface Area (BSA) at Baseline

The PhGAP is used to determine the participant's psoriasis lesions overall at a given time point. The participant's psoriasis disease activity is assessed by a physician according to the grades of induration, erythema, and scaling on a scale of 0 to 5. The sum of the three grades is used to obtain the total average score. PhGAP is based on the total average score on a scale of 0-5 where, 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate, 4 = marked, and 5 = severe. A negative change from baseline indicates improvement.

Time frame:
Baseline, 2, 4, 8, 12, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Physician's Global Assessment of Psoriasis (PhGAP) at Weeks 2, 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the Body Surface Area (BSA) at Baseline
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 2-1 ± 0.90 ± 0.70 ± 0.9
Change from Baseline at Week 4-1 ± 1.10 ± 0.70 ± 1.1
Change from Baseline at Week 8-1 ± 0.90 ± 0.8-1 ± 1.1
Change from Baseline at Week 12-1 ± 1.0-1 ± 0.7-1 ± 0.8
Change from Baseline at Week 16-2 ± 1.00 ± 0.70 ± 0.9
SecondaryChange From Baseline in PhGAP at Weeks 18, 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

The PhGAP is used to determine the participant's psoriasis lesions overall at a given time point. The participant's psoriasis disease activity is assessed by a physician according to the grades of induration, erythema, and scaling on a scale of 0 to 5. The sum of the three grades is used to obtain the total average score. PhGAP is based on the total average score on a scale of 0-5 where, 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate, 4 = marked, and 5 = severe. A negative change from baseline indicates improvement.

Time frame:
Baseline, 18, 20, 24, 28, 36, and 48 weeks
Reported as:
Mean · score on a scale
Change From Baseline in PhGAP at Weeks 18, 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 18-2 ± 1.4-1 ± 0.5-1 ± 0.60 ± 0.0
Change from Baseline at Week 20-1 ± 0.90 ± 0.9-1 ± 0.80 ± 0.0
Change from Baseline at Week 24-2 ± 1.10 ± 0.5-2 ± 0.8-1 ± 0.7
Change from Baseline at Week 28-1 ± 0.6-1 ± 0.4-1 ± 1.2-1 ± NA
Change from Baseline at Week 36-2 ± 0.60 ± 0.5-1 ± 0.80 ± NA
Change from Baseline at Week 48-1 ± 1.00 ± 0.4-1 ± 0.80 ± NA
SecondaryChange From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) at Weeks 4, 8, 12, and 16 in Participants With Psoriatic Nail Involvement at Baseline

mNAPSI is used to assess each nail abnormality for each of the participant's nails. Three features or groups of features (pitting, onycholysis together with oil-drop dyschromia, and crumbling) of each fingernail are graded on a scale from 0 (no onycholysis together with oil-drop dyschromia, no pitting, no crumbling) to 3 (\>30 onycholysis together with oil-drop dyschromia, \>50 pitting, \>50% crumbling). Four features (leukonychia, splinter, hemorrhages, hyperkeratosis, and red spots in the lunula) are graded with the score of 1 = present or 0 = absent for each fingernail. Each finger has a score between 0 and 13. The total mNAPSI score is the sum of all abnormalities individual score across all fingers, and the total mNAPSI score ranges from 0 to 130. Lower numbers indicate fewer nail abnormalities. A negative change from baseline indicates improvement.

Time frame:
Baseline, 4, 8, 12, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) at Weeks 4, 8, 12, and 16 in Participants With Psoriatic Nail Involvement at Baseline
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 4-6 ± 7.4-4 ± 8.50 ± 9.7
Change from Baseline at Week 8-7 ± 9.9-5 ± 11.10 ± 11.2
Change from Baseline at Week 12-7 ± 8.3-4 ± 11.71 ± 14.0
Change from Baseline at Week 16-8 ± 9.3-6 ± 9.4-2 ± 8.3
SecondaryChange From Baseline in mNAPSI at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriatic Nail Involvement at Baseline

mNAPSI is used to assess each nail abnormality for each of the participant's nails. Three features or groups of features (pitting, onycholysis together with oil-drop dyschromia, and crumbling) of each fingernail are graded on a scale from 0 (no onycholysis together with oil-drop dyschromia, no pitting, no crumbling) to 3 (\>30 onycholysis together with oil-drop dyschromia, \>50 pitting, \>50% crumbling). Four features (leukonychia, splinter, hemorrhages, hyperkeratosis, and red spots in the lunula) are graded with the score of 1 = present or 0 = absent for each fingernail. Each finger has a score between 0 and 13. The total mNAPSI score is the sum of all abnormalities individual score across all fingers, and the total mNAPSI score ranges from 0 to 130. Lower numbers indicate fewer nail abnormalities. A negative change from baseline indicates improvement.

Time frame:
Baseline, 20, 24, 28, 36, and 48 weeks
Reported as:
Mean · score on a scale
Change From Baseline in mNAPSI at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriatic Nail Involvement at Baseline
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 20-11 ± 12.3-5 ± 10.1-1 ± 4.8-3 ± 5.5
Change from Baseline at Week 24-10 ± 11.9-4 ± 7.5-2 ± 4.0-1 ± 1.4
Change from Baseline at Week 28-13 ± 15.4-5 ± 11.4-3 ± 4.9-3 ± 2.3
Change from Baseline at Week 36-13 ± 15.3-6 ± 8.42 ± 2.1-2 ± 1.2
Change from Baseline at Week 48-9 ± 16.6-3 ± 5.01 ± 5.6-8 ± 10.6
SecondaryChange From Baseline in Leeds Enthesitis Index (LEI) at Weeks 4, 8, 12, and 16 in Participants With Enthesitis at Baseline

Enthesitis is assessed using LEI. The enthesitis examination by LEI evaluates the presence or absence of pain by applying local pressure on 6 anatomical sites: medial femoral condyle (left and right), lateral epicondyle (left and right), and the achilles tendon insertion (left and right). Enthesitis at each site is scored as 0 (enthesitis absent) and 1 (enthesitis present). LEI is derived as the sum of the enthesitis score over the 6 sites mentioned above. The total score ranges from 0 to 6, higher scores indicates greater degree of enthesitis. A negative change from baseline indicates improvement.

Time frame:
Baseline, 4, 8, 12, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Leeds Enthesitis Index (LEI) at Weeks 4, 8, 12, and 16 in Participants With Enthesitis at Baseline
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 40 ± 1.3-1 ± 1.20 ± 1.9
Change from Baseline at Week 8-1 ± 2.40 ± 1.40 ± 1.6
Change from Baseline at Week 12-1 ± 2.10 ± 1.60 ± 1.5
Change from Baseline at Week 16-1 ± 2.4-1 ± 1.30 ± 1.4
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.24 (P-value was provided from mixed-effects model for repeated measures (MMRM) having treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -0 · 95% CI -1 to 0
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.22 (P-value was provided from MMRM having treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -1 · 95% CI -1 to 0
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.43 (P-value was provided from MMRM having treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -0 · 95% CI -1 to 1
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.70 (P-value was provided from MMRM having treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: 0 · 95% CI -1 to 1
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.10 (P-value was provided from MMRM having treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -1 · 95% CI -2 to 0
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.90 (P-value was provided from MMRM having treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -0 · 95% CI -1 to 1
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.88 (P-value was provided from MMRM having treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: 0 · 95% CI -1 to 1
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.89 (P-value was provided from MMRM having treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -0 · 95% CI -1 to 1
SecondaryChange From Baseline in LEI at Weeks 20, 24, 28, 36, and 48 in Participants With Enthesitis at Baseline

Enthesitis is assessed using LEI. The enthesitis examination by LEI evaluates the presence or absence of pain by applying local pressure on 6 anatomical sites: medial femoral condyle (left and right), lateral epicondyle (left and right), and the achilles tendon insertion (left and right). Enthesitis at each site is scored as 0 (enthesitis absent) and 1 (enthesitis present). LEI is derived as the sum of the enthesitis score over the 6 sites mentioned above. The total score ranges from 0 to 6, higher scores indicates greater degree of enthesitis. A negative change from baseline indicates improvement.

Time frame:
Baseline, 20, 24, 28, 36, and 48 weeks
Reported as:
Mean · score on a scale
Change From Baseline in LEI at Weeks 20, 24, 28, 36, and 48 in Participants With Enthesitis at Baseline
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 20-2 ± 2.2-1 ± 1.60 ± 1.30 ± 1.8
Change from Baseline at Week 24-1 ± 2.00 ± 1.40 ± 0.80 ± 0.4
Change from Baseline at Week 28-2 ± 1.9-1 ± 2.2-1 ± 1.00 ± 0.5
Change from Baseline at Week 36-2 ± 1.8-2 ± 2.40 ± 2.10 ± 1.0
Change from Baseline at Week 48-3 ± 1.4-2 ± 2.4-1 ± 1.01 ± 1.3
SecondaryChange From Baseline in 12-Item Psoriatic Arthritis Impact of Disease (PsAID-12) Score at Weeks 4 and 16

The PsAID questionnaire assesses the impact of PsA on people's lives. The PsAID is calculated based on 12 numerical rating scales (NRS) questions. The 12 NRS is focused on pain, fatigue, skin, work and/or leisure activities, function, discomfort, sleep, coping, anxiety, embarrassment, social life, and depression. Each NRS is assessed as a number between 0 and 10. Total score is calculated as the sum of the individual scores, (some of which were multiplied by a weighting factor) divided by 20 for a total possible score of 0 to 10, where higher score indicates worse impact of disease. A negative change from baseline indicates improvement.

Time frame:
Baseline, 4, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in 12-Item Psoriatic Arthritis Impact of Disease (PsAID-12) Score at Weeks 4 and 16
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 4-0.97 ± 1.876-0.66 ± 1.492-0.49 ± 1.139
Change from Baseline at Week 16-1.58 ± 2.263-1.04 ± 1.802-0.38 ± 1.543
SecondaryChange From Baseline in PsAID-12 Score at Week 48

The PsAID questionnaire assesses the impact of PsA on people's lives. The PsAID is calculated based on 12 numerical rating scales (NRS) questions. The 12 NRS is focused on pain, fatigue, skin, work and/or leisure activities, function, discomfort, sleep, coping, anxiety, embarrassment, social life, and depression. Each NRS is assessed as a number between 0 and 10. Total score is calculated as the sum of the individual scores, (some of which were multiplied by a weighting factor) divided by 20 for a total possible score of 0 to 10, where higher score indicates worse impact of disease. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 48
Reported as:
Mean · score on a scale
Change From Baseline in PsAID-12 Score at Week 48
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change From Baseline in PsAID-12 Score at Week 48-1.04 ± 2.441-1.44 ± 2.396-1.59 ± 1.8070.39 ± 1.123
SecondaryPercentage of Participants With PASDAS Low Disease Activity (LDA) at Weeks 4 and 16

PASDAS is a composite disease activity measure for psoriatic arthritis. The PASDAS includes the following components: PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\]; PhGADA \[using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity)\]; 36-item short form survey (SF-36) \[a questionnaire which measures quality of life across eight domains used to determine a PCS with a score range of 0-100, higher scores indicates better health status\]; TJC68; SJC66; LEI \[assessed at 6 sites with a score range of 0 to 6, higher scores indicates higher degree of enthesitis\]; TDC \[with a score range of 0 to 60, higher score indicates higher degree of dactylitis\]; CRP. The score of PASDAS ranges from 0-10, lower score indicates better function. PASDAS LDA is defined as PASDAS ≤ 3.2.

Time frame:
Weeks 4 and 16
Reported as:
Number · percentage of participants
Percentage of Participants With PASDAS Low Disease Activity (LDA) at Weeks 4 and 16
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 48.8 (0.0 to 19.8)21.2 (5.7 to 36.7)8.6 (0.0 to 19.3)
Week 1638.7 (20.0 to 57.5)30.3 (13.1 to 47.5)12.1 (0.0 to 24.8)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.3 · 95% CI -15.9 to 16.595% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 12.6 · 95% CI -7.1 to 32.395% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 26.6 · 95% CI 3.0 to 50.295% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 18.2 · 95% CI -4.1 to 40.495% CI for difference in response rates were based on normal approximation method with a continuity correction.
SecondaryPercentage of Participants With PASDAS LDA at Week 48

PASDAS is a composite disease activity measure for psoriatic arthritis. The PASDAS includes the following components: PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\]; PhGADA \[using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity)\]; 36-item short form survey (SF-36) \[a questionnaire which measures quality of life across eight domains used to determine a PCS with a score range of 0-100, higher scores indicates better health status\]; TJC68; SJC66; LEI \[assessed at 6 sites with a score range of 0 to 6, higher scores indicates higher degree of enthesitis\]; TDC \[with a score range of 0 to 60, higher score indicates higher degree of dactylitis\]; CRP. The score of PASDAS ranges from 0-10, lower score indicates better function. PASDAS LDA is defined as PASDAS ≤ 3.2.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With PASDAS LDA at Week 48
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Percentage of Participants With PASDAS LDA at Week 4850.0 (9.1 to 90.9)33.3 (0.0 to 69.7)50.0 (0.0 to 100.0)0 (0.0 to 16.7)
SecondaryPercentage of Participants Who Achieved PASDAS Remission at Weeks 4 and 16

PASDAS is a composite disease activity measure for psoriatic arthritis. The PASDAS includes the following components: PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\]; PhGADA \[using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity)\]; 36-item short form survey (SF-36) \[a questionnaire which measures quality of life across eight domains used to determine a PCS with a score range of 0-100, higher scores indicates better health status\]; TJC68; SJC66; LEI \[assessed at 6 sites with a score range of 0 to 6, higher scores indicates higher degree of enthesitis\]; TDC \[with a score range of 0 to 60, higher score indicates higher degree of dactylitis\]; CRP. The score of PASDAS ranges from 0-10, lower score indicates better function. PASDAS remission is defined as PASDAS ≤ 1.9.

Time frame:
Weeks 4 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASDAS Remission at Weeks 4 and 16
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 42.9 (0.0 to 10.1)0 (0.0 to 1.5)0 (0.0 to 1.4)
Week 1612.9 (0.0 to 26.3)9.1 (0.0 to 20.4)0 (0.0 to 1.5)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 2.9 · 95% CI -5.6 to 11.595% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.0 · 95% CI -2.9 to 2.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 12.9 · 95% CI -2.0 to 27.895% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 9.1 · 95% CI -3.7 to 21.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
SecondaryPercentage of Participants Who Achieved PASDAS Remission at Week 48

PASDAS is a composite disease activity measure for psoriatic arthritis. The PASDAS includes the following components: PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\]; PhGADA \[using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity)\]; 36-item short form survey (SF-36) \[a questionnaire which measures quality of life across eight domains used to determine a PCS with a score range of 0-100, higher scores indicates better health status\]; TJC68; SJC66; LEI \[assessed at 6 sites with a score range of 0 to 6, higher scores indicates higher degree of enthesitis\]; TDC \[with a score range of 0 to 60, higher score indicates higher degree of dactylitis\]; CRP. The score of PASDAS ranges from 0-10, lower score indicates better function. PASDAS remission is defined as PASDAS ≤ 1.9.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASDAS Remission at Week 48
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Percentage of Participants Who Achieved PASDAS Remission at Week 4825.0 (0.0 to 61.3)11.1 (0.0 to 37.2)25.0 (0.0 to 79.9)0 (0.0 to 16.7)
SecondaryPercentage of Participants Who Achieved an American College of Rheumatology 20% Improvement Response at Weeks 2, 4, 8, 12, and 16

ACR20 response is achieved when the participant has: ≥ 20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGADA using a VAS on a scale of 0 (very well) to 100 (very poor); PHGADA using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity); HAQ-DI inclusive of activities scored on a scale of 0 (no disability) to 3 (completely disabled); HAQ-DI pain assessment using VAS on a scale of 0 (no pain) to 100 (serious pain); and hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 2, 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology 20% Improvement Response at Weeks 2, 4, 8, 12, and 16
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 226.5 (10.2 to 42.8)6.1 (0.0 to 15.7)11.1 (0.0 to 22.8)
Week 431.4 (14.6 to 48.2)29.4 (12.6 to 46.2)20.6 (5.5 to 35.7)
Week 859.4 (40.8 to 78.0)32.4 (15.2 to 49.5)39.4 (21.2 to 57.6)
Week 1260.6 (42.4 to 78.8)35.3 (17.8 to 52.8)32.4 (15.2 to 49.5)
Week 1656.3 (37.5 to 75.0)36.4 (18.4 to 54.3)30.3 (13.1 to 47.5)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.098 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 15.4 · 95% CI -5.5 to 36.395% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.40 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: -5.1 · 95% CI -21.1 to 11.095% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.26 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 10.8 · 95% CI -12.6 to 34.395% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.39 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 8.8 · 95% CI -14.6 to 32.295% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.088 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 20.0 · 95% CI -6.9 to 46.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.49 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: -7.0 · 95% CI -32.9 to 18.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.019 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 28.3 · 95% CI 2.4 to 54.295% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.85 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 2.9 · 95% CI -22.5 to 28.495% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.036 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 25.9 · 95% CI -0.4 to 52.395% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.60 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 6.1 · 95% CI -19.7 to 31.895% CI for difference in response rates were based on normal approximation method with a continuity correction.
SecondaryPercentage of Participants Who Achieved an American College of Rheumatology 20% Improvement Response at Weeks 18, 20, 24, 28, 36, 48, and 60

ACR20 response is achieved when the participant has: ≥ 20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGADA using a VAS on a scale of 0 (very well) to 100 (very poor); PHGADA using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity); HAQ-DI inclusive of activities scored on a scale of 0 (no disability) to 3 (completely disabled); HAQ-DI pain assessment using VAS on a scale of 0 (no pain) to 100 (serious pain); and hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 18, 20, 24, 28, 36, 48, and 60
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology 20% Improvement Response at Weeks 18, 20, 24, 28, 36, 48, and 60
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Week 1866.7 (39.5 to 93.9)50.0 (24.1 to 75.9)42.9 (0.0 to 86.7)0 (0.0 to 7.1)
Week 2046.2 (15.2 to 77.1)47.4 (22.3 to 72.5)50.0 (9.1 to 90.9)12.5 (0.0 to 41.7)
Week 2446.2 (15.2 to 77.1)75.0 (50.7 to 99.3)0 (0.0 to 12.5)16.7 (0.0 to 54.8)
Week 2862.5 (22.7 to 100.0)72.7 (41.9 to 100.0)33.3 (0.0 to 100.0)20.0 (0.0 to 65.1)
Week 3677.8 (45.1 to 100.0)50.0 (14.0 to 86.0)0 (0.0 to 16.7)50.0 (0.0 to 100.0)
Week 4862.5 (22.7 to 100.0)44.4 (6.4 to 82.5)66.7 (0.0 to 100.0)0 (0.0 to 16.7)
Week 60100.0 (50.0 to 100.0)100.0 (50.0 to 100.0)100.0 (75.0 to 100.0)50.0 (0.0 to 100.0)
SecondaryPercentage of Participants Who Achieve an American College of Rheumatology 50% Improvement Response at Weeks 2, 4, 8, 12, and 16

ACR50 response is achieved when the participant has: ≥ 50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGADA using a VAS on a scale of 0 (very well) to 100 (very poor); PHGADA using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity); HAQ-DI inclusive of activities scored on a scale of 0 (no disability) to 3 (completely disabled); HAQ-DI pain assessment using VAS on a scale of 0 (no pain) to 100 (serious pain); and hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 2, 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve an American College of Rheumatology 50% Improvement Response at Weeks 2, 4, 8, 12, and 16
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 28.8 (0.0 to 19.8)0 (0.0 to 1.5)2.8 (0.0 to 9.5)
Week 411.1 (0.0 to 22.8)0 (0.0 to 1.5)8.6 (0.0 to 19.3)
Week 815.6 (1.5 to 29.8)8.8 (0.0 to 19.8)9.1 (0.0 to 20.4)
Week 1236.4 (18.4 to 54.3)8.8 (0.0 to 19.8)17.6 (3.4 to 31.9)
Week 1643.8 (25.0 to 62.5)18.2 (3.5 to 32.9)3.0 (0.0 to 10.4)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.31 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 6.0 · 95% CI -7.8 to 19.895% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.48 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: -2.8 · 95% CI -11.1 to 5.595% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.70 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 2.5 · 95% CI -14.1 to 19.295% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.17 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: -8.6 · 95% CI -20.7 to 3.695% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.34 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 6.5 · 95% CI -12.5 to 25.695% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.98 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: -0.3 · 95% CI -16.9 to 16.495% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.071 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 18.7 · 95% CI -5.1 to 42.595% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.27 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: -8.8 · 95% CI -27.7 to 10.195% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.002 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 40.7 · 95% CI 19.5 to 62.095% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.082 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 15.2 · 95% CI -2.3 to 32.695% CI for difference in response rates were based on normal approximation method with a continuity correction.
SecondaryPercentage of Participants Who Achieve an American College of Rheumatology 50% Improvement Response at Weeks 18, 20, 24, 28, 36, 48, and 60

ACR50 response is achieved when the participant has: ≥ 50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGADA using a VAS on a scale of 0 (very well) to 100 (very poor); PHGADA using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity); HAQ-DI inclusive of activities scored on a scale of 0 (no disability) to 3 (completely disabled); HAQ-DI pain assessment using VAS on a scale of 0 (no pain) to 100 (serious pain); and hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 18, 20, 24, 28, 36, 48, and 60
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve an American College of Rheumatology 50% Improvement Response at Weeks 18, 20, 24, 28, 36, 48, and 60
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Week 1840.0 (11.9 to 68.1)22.2 (0.2 to 44.2)28.6 (0.0 to 69.2)0 (0.0 to 6.3)
Week 2030.8 (1.8 to 59.7)21.1 (0.1 to 42.0)25.0 (0.0 to 61.3)0 (0.0 to 6.3)
Week 2438.5 (8.2 to 68.8)56.3 (28.8 to 83.7)0 (0.0 to 8.3)0 (0.0 to 8.3)
Week 2837.5 (0.0 to 77.3)18.2 (0.0 to 45.5)0 (0.0 to 16.7)0 (0.0 to 10.0)
Week 3666.7 (30.3 to 100.0)40.0 (4.6 to 75.4)0 (0.0 to 16.7)0 (0.0 to 10.0)
Week 4850.0 (9.1 to 90.9)11.1 (0.0 to 37.2)66.7 (0.0 to 100.0)0 (0.0 to 16.7)
Week 600 (0.0 to 50.0)0 (0.0 to 50.0)0 (0.0 to 25.0)50.0 (0.0 to 100.0)
SecondaryPercentage of Participants Who Achieve an American College of Rheumatology 70% Improvement Response at Weeks 2, 4, 8, 12, and 16

ACR70 response is achieved when the participant has: ≥ 70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGADA using a VAS on a scale of 0 (very well) to 100 (very poor); PHGADA using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity); HAQ-DI inclusive of activities scored on a scale of 0 (no disability) to 3 (completely disabled); HAQ-DI pain assessment using VAS on a scale of 0 (no pain) to 100 (serious pain); and hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 2, 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve an American College of Rheumatology 70% Improvement Response at Weeks 2, 4, 8, 12, and 16
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 22.9 (0.0 to 10.1)0 (0.0 to 1.5)0 (0.0 to 1.4)
Week 42.8 (0.0 to 9.5)0 (0.0 to 1.5)0 (0.0 to 1.4)
Week 815.6 (1.5 to 29.8)0 (0.0 to 1.5)2.9 (0.0 to 10.1)
Week 1221.2 (5.7 to 36.7)5.9 (0.0 to 15.3)2.9 (0.0 to 10.1)
Week 1612.5 (0.0 to 25.5)9.1 (0.0 to 20.4)0 (0.0 to 1.5)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 2.9 · 95% CI -5.6 to 11.595% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.0 · 95% CI -2.9 to 2.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 2.8 · 95% CI -5.4 to 11.095% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.0 · 95% CI -2.9 to 2.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 12.7 · 95% CI -4.2 to 29.595% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: -2.9 · 95% CI -11.6 to 5.795% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 18.3 · 95% CI 0.2 to 36.395% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 2.9 · 95% CI -9.7 to 15.695% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 12.5 · 95% CI -2.0 to 27.095% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 9.1 · 95% CI -3.7 to 21.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
SecondaryPercentage of Participants Who Achieve an American College of Rheumatology 70% Improvement Response at Weeks 18, 20, 24, 28, 36, 48, and 60

ACR70 response is achieved when the participant has: ≥ 70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGADA using a VAS on a scale of 0 (very well) to 100 (very poor); PHGADA using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity); HAQ-DI inclusive of activities scored on a scale of 0 (no disability) to 3 (completely disabled); HAQ-DI pain assessment using VAS on a scale of 0 (no pain) to 100 (serious pain); and hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 18, 20, 24, 28, 36, 48, and 60
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve an American College of Rheumatology 70% Improvement Response at Weeks 18, 20, 24, 28, 36, 48, and 60
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Week 1840.0 (11.9 to 68.1)11.1 (0.0 to 28.4)0 (0.0 to 6.3)0 (0.0 to 6.3)
Week 2030.8 (1.8 to 59.7)10.5 (0.0 to 27.0)0 (0.0 to 5.0)0 (0.0 to 6.3)
Week 2430.8 (1.8 to 59.7)25.0 (0.7 to 49.3)0 (0.0 to 8.3)0 (0.0 to 8.3)
Week 2837.5 (0.0 to 77.3)9.1 (0.0 to 30.6)0 (0.0 to 16.7)0 (0.0 to 10.0)
Week 3633.3 (0.0 to 69.7)10.0 (0.0 to 33.6)0 (0.0 to 12.5)0 (0.0 to 10.0)
Week 4825.0 (0.0 to 61.3)11.1 (0.0 to 37.2)0 (0.0 to 12.5)0 (0.0 to 16.7)
Week 600 (0.0 to 50.0)0 (0.0 to 50.0)0 (0.0 to 25.0)0 (0.0 to 25.0)
SecondaryChange From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 2, 4, 8, 12, and 16

TJC68 is an assessment of 68 joints. Each joint is evaluated as 'normal', 'tender', 'tender and swollen', or 'not able to evaluate'. It is derived as the sum of all tender joints. The overall tender joint count ranged from 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline indicates improvement.

Time frame:
Baseline, 2, 4, 8, 12, and 16 weeks
Reported as:
Mean · tender joint count
Change From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 2, 4, 8, 12, and 16
tender joint countFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 2-6 ± 10.3-5 ± 12.2-2 ± 11.9
Change from Baseline at Week 4-7 ± 10.7-7 ± 10.2-4 ± 13.9
Change from Baseline at Week 8-10 ± 13.2-8 ± 11.5-8 ± 13.2
Change from Baseline at Week 12-12 ± 15.4-10 ± 12.7-9 ± 10.7
Change from Baseline at Week 16-13 ± 15.7-11 ± 12.5-10 ± 10.7
SecondaryChange From Baseline in Individual ACR Component: TJC68 at Weeks 18, 20, 24, 28, 36, 48, and 60

TJC68 is an assessment of 68 joints. Each joint is evaluated as 'normal', 'tender', 'tender and swollen', or 'not able to evaluate'. It is derived as the sum of all tender joints. The overall tender joint count ranged from 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline indicates improvement.

Time frame:
Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks
Reported as:
Mean · tender joint count
Change From Baseline in Individual ACR Component: TJC68 at Weeks 18, 20, 24, 28, 36, 48, and 60
tender joint countFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 18-12 ± 14.8-12 ± 9.9-4 ± 4.6-2 ± 6.4
Change from Baseline at Week 20-18 ± 18.7-10 ± 12.2-4 ± 5.71 ± 8.9
Change from Baseline at Week 24-16 ± 25.6-11 ± 12.0-1 ± 2.3-1 ± 12.1
Change from Baseline at Week 28-21 ± 20.0-14 ± 14.20 ± 1.3-2 ± 13.4
Change from Baseline at Week 36-25 ± 19.6-13 ± 12.30 ± 1.9-5 ± 10.8
Change from Baseline at Week 48-22 ± 21.6-17 ± 14.7-6 ± 9.9-3 ± 14.0
Change from Baseline at Week 60-60 ± NA-11 ± NA-5 ± 3.53 ± 17.7
SecondaryChange From Baseline in ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 2, 4, 8, 12, and 16

SJC66 is an assessment of 66 joints. Each joint was evaluated as 'normal', 'swollen', 'tender and swollen', or 'not able to evaluate'. It is derived as the sum of all swollen joints. The overall swollen joint count ranged from 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline indicates improvement.

Time frame:
Baseline, 2, 4, 8, 12, and 16 weeks
Reported as:
Mean · swollen joint count
Change From Baseline in ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 2, 4, 8, 12, and 16
swollen joint countFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 2-3 ± 7.4-3 ± 5.60 ± 6.5
Change from Baseline at Week 4-6 ± 7.1-3 ± 4.4-3 ± 6.0
Change from Baseline at Week 8-7 ± 8.5-4 ± 5.0-4 ± 6.3
Change from Baseline at Week 12-8 ± 8.6-4 ± 7.2-4 ± 5.9
Change from Baseline at Week 16-7 ± 7.6-6 ± 6.9-5 ± 6.1
SecondaryChange From Baseline in ACR Component: SJC66 at Weeks 18, 20, 24, 28, 36, 48, and 60

SJC66 is an assessment of 66 joints. Each joint was evaluated as 'normal', 'swollen', 'tender and swollen', or 'not able to evaluate'. It is derived as the sum of all swollen joints. The overall swollen joint count ranged from 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline indicates improvement.

Time frame:
Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks
Reported as:
Mean · swollen joint count
Change From Baseline in ACR Component: SJC66 at Weeks 18, 20, 24, 28, 36, 48, and 60
swollen joint countFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 18-10 ± 7.7-8 ± 7.6-3 ± 3.2-1 ± 2.6
Change from Baseline at Week 20-11 ± 9.5-6 ± 6.0-3 ± 4.22 ± 6.6
Change from Baseline at Week 24-10 ± 9.9-6 ± 4.0-2 ± 4.1-1 ± 2.1
Change from Baseline at Week 28-14 ± 7.8-6 ± 4.20 ± 0.52 ± 6.9
Change from Baseline at Week 36-14 ± 7.1-7 ± 4.3-2 ± 3.3-1 ± 3.4
Change from Baseline at Week 48-13 ± 9.5-7 ± 4.1-6 ± 8.92 ± 4.9
Change from Baseline at Week 60-21 ± NA-2 ± NA-5 ± 2.82 ± 7.1
SecondaryChange From Baseline in Individual ACR Component: Patient's Global Assessment of Disease Activity (PGADA) at Weeks 2, 4, 8, 12, and 16

PGADA is assessed by the participants using a VAS on a scale of 0 (very well) to 100 (very poor). A negative change from baseline indicates improvement.

Time frame:
Baseline, 2, 4, 8, 12, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: Patient's Global Assessment of Disease Activity (PGADA) at Weeks 2, 4, 8, 12, and 16
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 2-13 ± 24.3-7 ± 18.6-4 ± 21.6
Change from Baseline at Week 4-9 ± 27.2-8 ± 19.2-9 ± 20.6
Change from Baseline at Week 8-20 ± 28.6-7 ± 21.9-11 ± 23.0
Change from Baseline at Week 12-24 ± 32.4-11 ± 19.4-8 ± 23.2
Change from Baseline at Week 16-21 ± 30.3-13 ± 24.2-5 ± 25.7
SecondaryChange From Baseline in Individual ACR Component: PGADA at Weeks 18, 20, 24, 28, 36, 48, and 60

PGADA is assessed by the participants using a VAS on a scale of 0 (very well) to 100 (very poor). A negative change from baseline indicates improvement.

Time frame:
Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: PGADA at Weeks 18, 20, 24, 28, 36, 48, and 60
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 18-24 ± 26.8-20 ± 25.4-13 ± 16.4-11 ± 21.5
Change from Baseline at Week 20-16 ± 30.0-18 ± 31.0-15 ± 25.3-9 ± 25.1
Change from Baseline at Week 24-12 ± 30.2-28 ± 34.3-19 ± 26.4-18 ± 9.8
Change from Baseline at Week 28-19 ± 27.9-24 ± 30.4-10 ± 34.0-21 ± 9.5
Change from Baseline at Week 36-26 ± 27.5-21 ± 30.611 ± 34.9-24 ± 8.6
Change from Baseline at Week 48-31 ± 17.0-23 ± 27.6-18 ± 21.6-6 ± 5.1
Change from Baseline at Week 60-32 ± NA-10 ± NA-14 ± 18.4-6 ± 12.0
SecondaryChange From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PhGADA) at Weeks 2, 4, 8, 12, and 16

PhGADA is assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

Time frame:
Baseline, 2, 4, 8, 12, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PhGADA) at Weeks 2, 4, 8, 12, and 16
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 2-14 ± 21.1-16 ± 14.5-8 ± 16.0
Change from Baseline at Week 4-20 ± 21.3-19 ± 15.8-12 ± 18.5
Change from Baseline at Week 8-31 ± 22.8-24 ± 14.1-17 ± 20.1
Change from Baseline at Week 12-34 ± 21.2-25 ± 17.9-15 ± 19.5
Change from Baseline at Week 16-35 ± 24.5-27 ± 20.3-18 ± 20.9
SecondaryChange From Baseline in Individual ACR Component: PhGADA at Weeks 18, 20, 24, 28, 36, 48, and 60

PhGADA is assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

Time frame:
Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: PhGADA at Weeks 18, 20, 24, 28, 36, 48, and 60
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 18-36 ± 24.0-29 ± 17.7-7 ± 14.0-6 ± 10.7
Change from Baseline at Week 20-32 ± 28.8-29 ± 15.4-14 ± 11.9-7 ± 8.9
Change from Baseline at Week 24-40 ± 24.8-29 ± 15.1-21 ± 15.0-8 ± 5.0
Change from Baseline at Week 28-43 ± 16.8-35 ± 14.4-27 ± 19.1-3 ± 22.3
Change from Baseline at Week 36-47 ± 19.6-37 ± 13.2-20 ± 13.1-8 ± 7.2
Change from Baseline at Week 48-46 ± 23.8-31 ± 12.9-25 ± 4.0-1 ± 2.3
Change from Baseline at Week 60-77 ± NA-33 ± NA-18 ± 13.4-16 ± 4.2
SecondaryChange From Baseline in Individual ACR Component: Health Assessment Questionnaire Disability Index (HAQ-DI)'s Pain Assessment at Weeks 2, 4, 8, 12, and 16

HAQ-DI's pain assessment is done using VAS on a scale of 0 (no pain) to 100 (serious pain). A negative change from baseline indicates improvement.

Time frame:
Baseline, 2, 4, 8, 12, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: Health Assessment Questionnaire Disability Index (HAQ-DI)'s Pain Assessment at Weeks 2, 4, 8, 12, and 16
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 2-10 ± 20.4-3 ± 12.0-4 ± 14.7
Change from Baseline at Week 4-10 ± 23.0-4 ± 17.0-8 ± 19.1
Change from Baseline at Week 8-17 ± 22.7-8 ± 21.3-12 ± 20.0
Change from Baseline at Week 12-24 ± 30.0-12 ± 22.2-6 ± 21.9
Change from Baseline at Week 16-22 ± 26.4-13 ± 21.7-6 ± 23.5
SecondaryChange From Baseline in Individual ACR Component: Health Assessment Questionnaire Disability Index (HAQ-DI)'s Pain Assessment at Weeks 18, 20, 24, 28, 36, 48, and 60

HAQ-DI's pain assessment is done using VAS on a scale of 0 (no pain) to 100 (serious pain). A negative change from baseline indicates improvement.

Time frame:
Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: Health Assessment Questionnaire Disability Index (HAQ-DI)'s Pain Assessment at Weeks 18, 20, 24, 28, 36, 48, and 60
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 18-26 ± 26.3-13 ± 24.7-18 ± 25.5-7 ± 8.5
Change from Baseline at Week 20-13 ± 30.3-18 ± 24.5-19 ± 24.5-7 ± 23.5
Change from Baseline at Week 24-18 ± 30.0-25 ± 29.4-17 ± 22.0-12 ± 12.7
Change from Baseline at Week 28-23 ± 20.7-19 ± 26.6-21 ± 25.0-21 ± 4.2
Change from Baseline at Week 36-27 ± 23.7-24 ± 23.4-2 ± 25.4-17 ± 8.4
Change from Baseline at Week 48-30 ± 22.4-23 ± 28.0-24 ± 23.6-8 ± 5.5
Change from Baseline at Week 60-22 ± NA-35 ± NA-20 ± 28.3-23 ± 2.8
SecondaryChange From Baseline in Individual ACR Component: High-Sensitivity C- Reactive Protein (hsCRP) at Weeks 2, 4, 8, 12, and 16

The hsCRP is the ACR core set measure of acute phase reactant. It was measured at the central laboratory to help assess the effect of filgotinib on the participant's psoriatic arthritis. A negative change from baseline indicates improvement.

Time frame:
Baseline, 2, 4, 8, 12, and 16 weeks
Reported as:
Mean · mg/L
Change From Baseline in Individual ACR Component: High-Sensitivity C- Reactive Protein (hsCRP) at Weeks 2, 4, 8, 12, and 16
mg/LFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 2-4.01 ± 6.6690.53 ± 14.9720.56 ± 8.836
Change from Baseline at Week 4-4.42 ± 10.769-1.20 ± 6.3090.05 ± 5.566
Change from Baseline at Week 8-5.21 ± 16.030-1.68 ± 5.085-1.35 ± 11.841
Change from Baseline at Week 12-4.57 ± 12.585-2.43 ± 6.248-1.09 ± 11.687
Change from Baseline at Week 16-4.96 ± 13.906-0.05 ± 7.210-0.37 ± 13.337
SecondaryChange From Baseline in Individual ACR Component: hsCRP at Weeks 18, 20, 24, 28, 36, 48, and 60

The hsCRP is the ACR core set measure of acute phase reactant. It was measured at the central laboratory to help assess the effect of filgotinib on the participant's psoriatic arthritis. A negative change from baseline indicates improvement.

Time frame:
Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks
Reported as:
Mean · mg/L
Change From Baseline in Individual ACR Component: hsCRP at Weeks 18, 20, 24, 28, 36, 48, and 60
mg/LFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 18-1.49 ± 5.017-0.70 ± 4.064-3.54 ± 6.980-3.05 ± 2.871
Change from Baseline at Week 20-0.68 ± 4.040-1.36 ± 4.214-3.83 ± 6.244-2.49 ± 3.285
Change from Baseline at Week 24-3.31 ± 5.963-2.21 ± 4.515-1.01 ± 5.187-1.72 ± 4.828
Change from Baseline at Week 281.56 ± 6.011-0.92 ± 5.4602.24 ± 7.159-2.33 ± 2.777
Change from Baseline at Week 36-3.10 ± 5.507-0.84 ± 7.796-1.92 ± 1.217-2.38 ± 1.959
Change from Baseline at Week 48-1.84 ± 6.2620.07 ± 6.378-2.08 ± 2.353-1.68 ± 1.992
Change from Baseline at Week 60-1.65 ± NA-12.32 ± NA2.39 ± 4.851-2.73 ± 0.827
SecondaryChange From Baseline in Disease Activity Score 28 (DAS28) C-Reactive Protein (CRP) at Weeks 2, 4, 8, 12, and 16

The DAS28(CRP) is a measure of the participant's disease activity calculated using the tender joint count (28 joints), swollen joint count (28 joints), PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\] and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

Time frame:
Baseline, 2, 4, 8, 12, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Disease Activity Score 28 (DAS28) C-Reactive Protein (CRP) at Weeks 2, 4, 8, 12, and 16
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 2-1.0 ± 1.09-0.7 ± 0.69-0.2 ± 0.70
Change from Baseline at Week 4-1.2 ± 1.18-0.7 ± 0.78-0.7 ± 1.18
Change from Baseline at Week 8-1.5 ± 1.18-1.1 ± 0.99-1.1 ± 1.41
Change from Baseline at Week 12-1.8 ± 1.37-1.3 ± 1.21-1.0 ± 1.10
Change from Baseline at Week 16-1.7 ± 1.35-1.3 ± 1.04-1.0 ± 1.26
SecondaryChange From Baseline in DAS28(CRP) at Weeks 18, 20, 24, 28, 36, 48 and 60

The DAS28(CRP) is a measure of the participant's disease activity calculated using the tender joint count (28 joints), swollen joint count (28 joints), PGADA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\] and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

Time frame:
Baseline, 18, 20, 24, 28, 36, 48 and 60 weeks
Reported as:
Mean · score on a scale
Change From Baseline in DAS28(CRP) at Weeks 18, 20, 24, 28, 36, 48 and 60
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 18-2.1 ± 1.37-1.8 ± 0.84-0.9 ± 0.70-0.4 ± 0.92
Change from Baseline at Week 20-1.9 ± 1.34-1.7 ± 0.90-1.1 ± 0.71-0.2 ± 1.34
Change from Baseline at Week 24-1.8 ± 1.75-1.9 ± 1.13-0.8 ± 0.66-0.7 ± 1.37
Change from Baseline at Week 28-2.1 ± 1.10-2.2 ± 0.84-0.9 ± 0.73-0.5 ± 1.79
Change from Baseline at Week 36-2.9 ± 1.38-2.1 ± 1.00-0.6 ± 1.30-0.5 ± 1.10
Change from Baseline at Week 48-2.7 ± 1.37-2.2 ± 0.93-1.3 ± 0.670.5 ± 1.62
Change from Baseline at Week 60-4.9 ± NA-0.4 ± NA-0.7 ± 0.140.1 ± 2.61
SecondaryPercentage of Participants Who Achieved DAS28(CRP) LDA at Weeks 2, 4, 8, 12, and 16

The DAS28 (CRP) is a measure of the participant's disease activity calculated using the tender joint count (28 joints), swollen joint count (28 joints), PGADA (VAS; 0 = very well to 100 = very poor), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. DAS28 (CRP) LDA is defined as DAS28(CRP) ≤ 3.2.

Time frame:
Weeks 2, 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAS28(CRP) LDA at Weeks 2, 4, 8, 12, and 16
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 220.6 (5.5 to 35.7)18.2 (3.5 to 32.9)11.1 (0.0 to 22.8)
Week 440.0 (22.3 to 57.7)26.5 (10.2 to 42.8)20.0 (5.3 to 34.7)
Week 853.1 (34.3 to 72.0)38.2 (20.4 to 56.0)35.3 (17.8 to 52.8)
Week 1251.5 (32.9 to 70.1)41.2 (23.2 to 59.2)26.5 (10.2 to 42.8)
Week 1654.8 (35.7 to 74.0)42.4 (24.0 to 60.8)36.4 (18.4 to 54.3)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 9.5 · 95% CI -10.4 to 29.495% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 7.1 · 95% CI -12.5 to 26.795% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 20.0 · 95% CI -3.8 to 43.895% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 6.5 · 95% CI -16.3 to 29.395% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 17.8 · 95% CI -8.8 to 44.595% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 2.9 · 95% CI -22.9 to 28.895% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 25.0 · 95% CI -0.5 to 50.695% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 14.7 · 95% CI -10.5 to 39.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 18.5 · 95% CI -8.7 to 45.695% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 6.1 · 95% CI -20.5 to 32.695% CI for difference in response rates were based on normal approximation method with a continuity correction.
SecondaryPercentage of Participants Who Achieved DAS28(CRP) LDA at Weeks 18, 20, 24, 28, 36, 48, and 60

The DAS28 (CRP) is a measure of the participant's disease activity calculated using the tender joint count (28 joints), swollen joint count (28 joints), PGADA (VAS; 0 = very well to 100 = very poor), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. DAS28 (CRP) LDA is defined as DAS28(CRP) ≤ 3.2.

Time frame:
Weeks 18, 20, 24, 28, 36, 48, and 60
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAS28(CRP) LDA at Weeks 18, 20, 24, 28, 36, 48, and 60
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Week 1860.0 (31.9 to 88.1)66.7 (42.1 to 91.2)62.5 (22.7 to 100.0)50.0 (9.1 to 90.9)
Week 2038.5 (8.2 to 68.8)47.4 (22.3 to 72.5)100.0 (95.0 to 100.0)37.5 (0.0 to 77.3)
Week 2438.5 (8.2 to 68.8)75.0 (50.7 to 99.3)71.4 (30.8 to 100.0)71.4 (30.8 to 100.0)
Week 2850.0 (9.1 to 90.9)100.0 (95.5 to 100.0)100.0 (87.5 to 100.0)25.0 (0.0 to 79.9)
Week 3677.8 (45.1 to 100.0)90.0 (66.4 to 100.0)50.0 (0.0 to 100.0)40.0 (0.0 to 92.9)
Week 4875.0 (38.7 to 100.0)88.9 (62.8 to 100.0)100.0 (87.5 to 100.0)0 (0.0 to 16.7)
Week 60100.0 (50.0 to 100.0)0 (0.0 to 50.0)50.0 (0.0 to 100.0)50.0 (0.0 to 100.0)
SecondaryPercentage of Participants Who Achieved DAS28(CRP) Remission at Weeks 2, 4, 8, 12, and 16

The DAS28 (CRP) is a measure of the participant's disease activity calculated using the tender joint count (28 joints), swollen joint count (28 joints), PGADA (VAS; 0 = very well to 100 = very poor), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. DAS28 (CRP) remission is defined as DAS28 (CRP) \< 2.6.

Time frame:
Weeks 2, 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAS28(CRP) Remission at Weeks 2, 4, 8, 12, and 16
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 211.8 (0.0 to 24.1)6.1 (0.0 to 15.7)2.8 (0.0 to 9.5)
Week 420.0 (5.3 to 34.7)8.8 (0.0 to 19.8)14.3 (1.3 to 27.3)
Week 821.9 (6.0 to 37.8)20.6 (5.5 to 35.7)20.6 (5.5 to 35.7)
Week 1233.3 (15.7 to 50.9)32.4 (15.2 to 49.5)11.8 (0.0 to 24.1)
Week 1638.7 (20.0 to 57.5)24.2 (8.1 to 40.4)21.2 (5.7 to 36.7)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 9.0 · 95% CI -6.0 to 23.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 3.3 · 95% CI -9.4 to 15.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 5.7 · 95% CI -14.7 to 26.295% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: -5.5 · 95% CI -23.4 to 12.495% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 1.3 · 95% CI -21.5 to 24.195% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.0 · 95% CI -22.2 to 22.295% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 21.6 · 95% CI -0.8 to 43.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 20.6 · 95% CI -1.4 to 42.695% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 17.5 · 95% CI -7.7 to 42.795% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 3.0 · 95% CI -20.2 to 26.395% CI for difference in response rates were based on normal approximation method with a continuity correction.
SecondaryPercentage of Participants Who Achieved DAS28(CRP) Remission at Weeks 18, 20, 24, 28, 36, 48, and 60

The DAS28 (CRP) is a measure of the participant's disease activity calculated using the tender joint count (28 joints), swollen joint count (28 joints), PGADA (VAS; 0 = very well to 100 = very poor), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. DAS28 (CRP) remission is defined as DAS28 (CRP) \< 2.6.

Time frame:
Weeks 18, 20, 24, 28, 36, 48, and 60
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAS28(CRP) Remission at Weeks 18, 20, 24, 28, 36, 48, and 60
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Week 1853.3 (24.8 to 81.9)44.4 (18.7 to 70.2)62.5 (22.7 to 100.0)25.0 (0.0 to 61.3)
Week 2030.8 (1.8 to 59.7)31.6 (8.0 to 55.1)60.0 (24.6 to 95.4)25.0 (0.0 to 61.3)
Week 2438.5 (8.2 to 68.8)62.5 (35.7 to 89.3)57.1 (13.3 to 100.0)42.9 (0.0 to 86.7)
Week 2850.0 (9.1 to 90.9)63.6 (30.7 to 96.6)75.0 (20.1 to 100.0)25.0 (0.0 to 79.9)
Week 3655.6 (17.5 to 93.6)50.0 (14.0 to 86.0)50.0 (0.0 to 100.0)20.0 (0.0 to 65.1)
Week 4862.5 (22.7 to 100.0)55.6 (17.5 to 93.6)100.0 (87.5 to 100.0)0 (0.0 to 16.7)
Week 60100.0 (50.0 to 100.0)0 (0.0 to 50.0)50.0 (0.0 to 100.0)50.0 (0.0 to 100.0)
SecondaryTime to Achieve DAS28(CRP) LDA

The DAS28 (CRP) is a measure of the participant's disease activity calculated using the TJC (28 joints), SJC (28 joints), PGADA (VAS; 0 = very well to 100 = very poor), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. DAS28 (CRP) LDA is defined as DAS28 (CRP) ≤ 3.2. Time to achieve DAS28(CRP) LDA is the number of days from the first dose date of study drug administration to the first time when a participant achieves DAS28(CRP) LDA.

Time frame:
Approximately 16 weeks
Reported as:
Median · days
Time to Achieve DAS28(CRP) LDA
daysFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Time to Achieve DAS28(CRP) LDA57 (29 to 113)NA (30 to NA)115 (56 to NA)
SecondaryPercentage of Participants Who Achieved DAPSA LDA at Weeks 2, 4, 8, 12, and 16

DAPSA is calculated by summing the following components: TJC68; SJC66; PGADA \[using VAS on a scale of 0 (very well) to 100 very poor)\]; PGAPI \[using a VAS on a scale of 0 (no pain) to 100 (serious pain)\] and CRP. DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. DAPSA LDA is defined as DAPSA ≤ 14.

Time frame:
Weeks 2, 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAPSA LDA at Weeks 2, 4, 8, 12, and 16
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 217.6 (3.4 to 31.9)12.1 (0.0 to 24.8)8.3 (0.0 to 18.8)
Week 425.7 (9.8 to 41.6)17.6 (3.4 to 31.9)20.0 (5.3 to 34.7)
Week 840.6 (22.0 to 59.2)29.4 (12.6 to 46.2)35.3 (17.8 to 52.8)
Week 1251.5 (32.9 to 70.1)41.2 (23.2 to 59.2)32.4 (15.2 to 49.5)
Week 1654.8 (35.7 to 74.0)39.4 (21.2 to 57.6)36.4 (18.4 to 54.3)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 9.3 · 95% CI -9.2 to 27.8
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 3.8 · 95% CI -13.5 to 21.0
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 5.7 · 95% CI -16.8 to 28.2
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: -2.4 · 95% CI -23.7 to 19.0
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 5.3 · 95% CI -21.1 to 31.8
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: -5.9 · 95% CI -31.0 to 19.3
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 19.2 · 95% CI -7.0 to 45.3
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 8.8 · 95% CI -16.9 to 34.6
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 18.5 · 95% CI -8.7 to 45.6
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 3.0 · 95% CI -23.4 to 29.5
SecondaryPercentage of Participants Who Achieved DAPSA LDA at Weeks 18, 20, 24, 28, 36, 48, and 60

DAPSA is calculated by summing the following components: TJC68; SJC66; PGADA \[using VAS on a scale of 0 (very well) to 100 very poor)\]; PGAPI \[using a VAS on a scale of 0 (no pain) to 100 (serious pain)\] and CRP. DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. DAPSA LDA is defined as DAPSA ≤ 14.

Time frame:
Weeks 18, 20, 24, 28, 36, 48, and 60
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAPSA LDA at Weeks 18, 20, 24, 28, 36, 48, and 60
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Week 1853.3 (24.8 to 81.9)50.0 (24.1 to 75.9)75.0 (38.7 to 100.0)50.0 (9.1 to 90.9)
Week 2030.8 (1.8 to 59.7)47.4 (22.3 to 72.5)80.0 (50.2 to 100.0)37.5 (0.0 to 77.3)
Week 2438.5 (8.2 to 68.8)75.0 (50.7 to 99.3)71.4 (30.8 to 100.0)42.9 (0.0 to 86.7)
Week 2862.5 (22.7 to 100.0)72.7 (41.9 to 100.0)100.0 (87.5 to 100.0)50.0 (0.0 to 100.0)
Week 3666.7 (30.3 to 100.0)60.0 (24.6 to 95.4)50.0 (0.0 to 100.0)60.0 (7.1 to 100.0)
Week 4862.5 (22.7 to 100.0)77.8 (45.1 to 100.0)75.0 (20.1 to 100.0)33.3 (0.0 to 100.0)
Week 600 (0.0 to 50.0)0 (0.0 to 50.0)50.0 (0.0 to 100.0)50.0 (0.0 to 100.0)
SecondaryPercentage of Participants Who Achieved DAPSA Remission at Weeks 2, 4, 8, 12, and 16

DAPSA is calculated by summing the following components: TJC68; SJC66; PGADA \[using VAS on a scale of 0 (very well) to 100 very poor)\]; PGAPI \[using a VAS on a scale of 0 (no pain) to 100 (serious pain)\] and CRP. DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. DAPSA remission is defined as DAPSA ≤ 4.

Time frame:
Weeks 2, 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAPSA Remission at Weeks 2, 4, 8, 12, and 16
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 20 (0.0 to 1.5)3.0 (0.0 to 10.4)2.8 (0.0 to 9.5)
Week 42.9 (0.0 to 9.8)0 (0.0 to 1.5)5.7 (0.0 to 14.8)
Week 89.4 (0.0 to 21.0)2.9 (0.0 to 10.1)8.8 (0.0 to 19.8)
Week 1215.2 (1.4 to 28.9)5.9 (0.0 to 15.3)2.9 (0.0 to 10.1)
Week 1616.1 (1.6 to 30.7)15.2 (1.4 to 28.9)3.0 (0.0 to 10.4)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: -2.8 · 95% CI -11.0 to 5.4
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.3 · 95% CI -10.6 to 11.1
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: -2.9 · 95% CI -15.2 to 9.5
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: -5.7 · 95% CI -16.3 to 4.9
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.6 · 95% CI -16.4 to 17.5
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: -5.9 · 95% CI -19.9 to 8.2
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 12.2 · 95% CI -4.3 to 28.7
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 2.9 · 95% CI -9.7 to 15.6
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 13.1 · 95% CI -4.2 to 30.4
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 12.1 · 95% CI -4.5 to 28.7
SecondaryPercentage of Participants Who Achieved DAPSA Remission at Weeks 18, 20, 24, 28, 36, 48, and 60

DAPSA is calculated by summing the following components: TJC68; SJC66; PGADA \[using VAS on a scale of 0 (very well) to 100 very poor)\]; PGAPI \[using a VAS on a scale of 0 (no pain) to 100 (serious pain)\] and CRP. DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. DAPSA remission is defined as DAPSA ≤ 4.

Time frame:
Weeks 18, 20, 24, 28, 36, 48, and 60
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAPSA Remission at Weeks 18, 20, 24, 28, 36, 48, and 60
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Week 1846.7 (18.1 to 75.2)16.7 (0.0 to 36.7)50.0 (9.1 to 90.9)12.5 (0.0 to 41.7)
Week 2023.1 (0.0 to 49.8)15.8 (0.0 to 34.8)20.0 (0.0 to 49.8)0 (0.0 to 6.3)
Week 2430.8 (1.8 to 59.7)43.8 (16.3 to 71.2)28.6 (0.0 to 69.2)14.3 (0.0 to 47.4)
Week 2837.5 (0.0 to 77.3)18.2 (0.0 to 45.5)50.0 (0.0 to 100.0)0 (0.0 to 12.5)
Week 3655.6 (17.5 to 93.6)10.0 (0.0 to 33.6)25.0 (0.0 to 79.9)0 (0.0 to 10.0)
Week 4850.0 (9.1 to 90.9)22.2 (0.0 to 54.9)75.0 (20.1 to 100.0)0 (0.0 to 16.7)
Week 600 (0.0 to 50.0)0 (0.0 to 50.0)50.0 (0.0 to 100.0)0 (0.0 to 25.0)
SecondaryTime to Achieve DAPSA LDA

DAPSA is calculated by summing the following components: TJC68; SJC66; PGADA \[using VAS on a scale of 0 (very well) to 100 very poor)\]; PGAPI \[using a VAS on a scale of 0 (no pain) to 100 (serious pain)\] and CRP. DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \>28 = high disease activity. DAPSA LDA is defined as DAPSA ≤ 14. Time to achieve DAPSA LDA is the number of days from the first dose date of study drug administration to the first time when a participant achieves DAPSA LDA. If the DAPSA LDA is not achieved during main study phase, the time to achieve DAPSA LDA will be censored at the last non-missing DAPSA LDA assessment date during main study phase. If the component scores of DAPSA LDA are at different dates for a visit, the latest date will be used for the derivation of time to achieve DAPSA LDA.

Time frame:
Approximately 16 weeks
Reported as:
Median · days
Time to Achieve DAPSA LDA
daysFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Time to Achieve DAPSA LDA84 (29 to 114)NA (58 to NA)NA (55 to NA)
SecondaryPercentage of Participants Who Achieved Psoriatic Arthritis Response Criteria (PsARC) Response at Weeks 2, 4, 8, 12, and 16

The PsARC response was defined as improvement in at least 2 of the following 4 criteria; ≥ 30% decrease in SJC66, ≥ 30% decrease in TJC68, ≥ 20% decrease in PGADA (VAS; 0 = very well to 100 = very poor), ≥ 20% decrease in PhGADA (VAS; 0 = no disease activity to 100 = maximum disease activity) and with at least one of the 2 joint criteria, with no deterioration in any other criteria.

Time frame:
Weeks 2, 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Psoriatic Arthritis Response Criteria (PsARC) Response at Weeks 2, 4, 8, 12, and 16
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 232.4 (15.2 to 49.5)21.2 (5.7 to 36.7)13.9 (1.2 to 26.6)
Week 441.7 (24.2 to 59.2)41.2 (23.2 to 59.2)25.7 (9.8 to 41.6)
Week 868.8 (51.1 to 86.4)44.1 (26.0 to 62.3)50.0 (31.7 to 68.3)
Week 1275.8 (59.6 to 91.9)58.8 (40.8 to 76.8)35.3 (17.8 to 52.8)
Week 1662.5 (44.2 to 80.8)48.5 (29.9 to 67.1)42.4 (24.0 to 60.8)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 18.5 · 95% CI -3.8 to 40.795% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 7.3 · 95% CI -13.5 to 28.295% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 16.0 · 95% CI -8.5 to 40.495% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 15.5 · 95% CI -9.4 to 40.395% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 18.8 · 95% CI -7.5 to 45.095% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: -5.9 · 95% CI -32.5 to 20.795% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 40.5 · 95% CI 15.8 to 65.295% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 23.5 · 95% CI -2.5 to 49.595% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 20.1 · 95% CI -6.8 to 46.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 6.1 · 95% CI -21.0 to 33.195% CI for difference in response rates were based on normal approximation method with a continuity correction.
SecondaryPercentage of Participants Who Achieved PsARC Response at Weeks 18, 20, 24, 28, 36, 48, and 60

The PsARC response was defined as improvement in at least 2 of the following 4 criteria; ≥ 30% decrease in SJC66, ≥ 30% decrease in TJC68, ≥ 20% decrease in PGADA (VAS; 0 = very well to 100 = very poor), ≥ 20% decrease in PhGADA (VAS; 0 = no disease activity to 100 = maximum disease activity) and with at least one of the 2 joint criteria, with no deterioration in any other criteria.

Time frame:
Weeks 18, 20, 24, 28, 36, 48, and 60
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PsARC Response at Weeks 18, 20, 24, 28, 36, 48, and 60
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Week 1873.3 (47.6 to 99.0)83.3 (63.3 to 100.0)42.9 (0.0 to 86.7)28.6 (0.0 to 69.2)
Week 2061.5 (31.2 to 91.8)68.4 (44.9 to 92.0)44.4 (6.4 to 82.5)28.6 (0.0 to 69.2)
Week 2453.8 (22.9 to 84.8)68.8 (42.9 to 94.6)16.7 (0.0 to 54.8)16.7 (0.0 to 54.8)
Week 2875.0 (38.7 to 100.0)63.6 (30.7 to 96.6)50.0 (0.0 to 100.0)0 (0.0 to 10.0)
Week 3688.9 (62.8 to 100.0)70.0 (36.6 to 100.0)25.0 (0.0 to 79.9)20.0 (0.0 to 65.1)
Week 4887.5 (58.3 to 100.0)66.7 (30.3 to 100.0)100.0 (87.5 to 100.0)0 (0.0 to 16.7)
Week 60100.0 (50.0 to 100.0)100.0 (50.0 to 100.0)50.0 (0.0 to 100.0)0 (0.0 to 25.0)
SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, where 0 = none, 1 = mild, 2 = moderate, 3 = severe and 4 = very severe, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). A higher score indicates more severe disease. A negative change from baseline indicates improvement.

Time frame:
Baseline, 4, 8, 12, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 4-1.8 ± 2.79-2.0 ± 3.70-1.5 ± 7.87
Change from Baseline at Week 8-3.6 ± 4.82-1.7 ± 5.27-4.3 ± 6.30
Change from Baseline at Week 12-4.5 ± 6.79-2.3 ± 5.28-4.9 ± 7.10
Change from Baseline at Week 16-5.5 ± 6.90-1.0 ± 7.34-5.4 ± 6.10
SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, where 0 = none, 1 = mild, 2 = moderate, 3 = severe and 4 = very severe, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). A higher score indicates more severe disease. A negative change from baseline indicates improvement.

Time frame:
Baseline, 20, 24, 28, 36, and 48 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 20-0.4 ± 7.20-2.9 ± 3.83-2.0 ± 2.21-1.3 ± 1.84
Change from Baseline at Week 24-2.9 ± 3.25-2.6 ± 3.06-2.9 ± 2.45-1.9 ± 2.69
Change from Baseline at Week 28-2.5 ± 2.37-4.4 ± 3.65-2.0 ± 2.62-4.0 ± NA
Change from Baseline at Week 36-2.3 ± 2.34-1.0 ± 4.68-2.4 ± 2.30-3.8 ± NA
Change from Baseline at Week 48-1.7 ± 1.54-2.0 ± 3.77-1.8 ± 1.41-2.6 ± NA
SecondaryPercentage of Participants Who Achieved Psoriasis Area and Severity Index 50% Improvement (PASI50) Response at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI50, the improvement threshold from baseline in PASI score is 50%. A higher score indicates more severe disease.

Time frame:
Weeks 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Psoriasis Area and Severity Index 50% Improvement (PASI50) Response at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 413.3 (0.0 to 33.9)35.3 (9.6 to 61.0)13.3 (0.0 to 33.9)
Week 840.0 (11.9 to 68.1)41.2 (14.8 to 67.5)35.7 (7.0 to 64.4)
Week 1260.0 (31.9 to 88.1)29.4 (4.8 to 54.0)42.9 (13.4 to 72.4)
Week 1664.3 (35.6 to 93.0)35.3 (9.6 to 61.0)35.7 (7.0 to 64.4)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.0 · 95% CI -31.0 to 31.095% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 22.0 · 95% CI -12.8 to 56.795% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 4.3 · 95% CI -37.9 to 46.595% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 5.5 · 95% CI -35.4 to 46.395% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 17.1 · 95% CI -25.6 to 59.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: -13.4 · 95% CI -53.7 to 26.895% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 28.6 · 95% CI -14.1 to 71.295% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: -0.4 · 95% CI -40.8 to 39.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
SecondaryPercentage of Participants Who Achieved PASI50 Response at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI50, the improvement threshold from baseline in PASI score is 50%. A higher score indicates more severe disease.

Time frame:
Weeks 20, 24, 28, 36, and 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI50 Response at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Week 2057.1 (13.3 to 100.0)57.1 (13.3 to 100.0)40.0 (0.0 to 92.9)0 (0.0 to 25.0)
Week 2483.3 (45.2 to 100.0)57.1 (13.3 to 100.0)75.0 (20.1 to 100.0)50.0 (0.0 to 100.0)
Week 28100.0 (75.0 to 100.0)66.7 (20.6 to 100.0)66.7 (0.0 to 100.0)100.0 (50.0 to 100.0)
Week 3666.7 (0.0 to 100.0)60.0 (7.1 to 100.0)75.0 (20.1 to 100.0)100.0 (50.0 to 100.0)
Week 4866.7 (0.0 to 100.0)60.0 (7.1 to 100.0)50.0 (0.0 to 100.0)0 (0.0 to 50.0)
SecondaryPercentage of Participants Who Achieved Psoriasis Area and Severity Index 75% Improvement (PASI75) Response at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI75, the improvement threshold from baseline in PASI score is 75%. A higher score indicates more severe disease.

Time frame:
Weeks 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Psoriasis Area and Severity Index 75% Improvement (PASI75) Response at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 413.3 (0.0 to 33.9)17.6 (0.0 to 38.7)6.7 (0.0 to 22.6)
Week 813.3 (0.0 to 33.9)17.6 (0.0 to 38.7)7.1 (0.0 to 24.2)
Week 1240.0 (11.9 to 68.1)17.6 (0.0 to 38.7)21.4 (0.0 to 46.5)
Week 1642.9 (13.4 to 72.4)23.5 (0.4 to 46.6)21.4 (0.0 to 46.5)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.55 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 6.7 · 95% CI -21.3 to 34.795% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.24 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 11.0 · 95% CI -17.4 to 39.395% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.47 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 6.2 · 95% CI -22.6 to 35.095% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.25 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 10.5 · 95% CI -18.6 to 39.695% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.44 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 18.6 · 95% CI -21.1 to 58.395% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.68 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: -3.8 · 95% CI -38.4 to 30.895% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.33 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 21.4 · 95% CI -19.4 to 62.295% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Regression, Logistic · p = 0.98 (P-value was calculated from the logistic regression with treatment groups and stratification factors (geographic region, concurrent use of csDMARD(s) and/or apremilast at randomization, prior use of bioDMARD(s)) in the model.) · Difference in response rates: 2.1 · 95% CI -33.9 to 38.195% CI for difference in response rates were based on normal approximation method with a continuity correction.
SecondaryPercentage of Participants Who Achieved PASI75 Response at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI75, the improvement threshold from baseline in PASI score is 75%. A higher score indicates more severe disease.

Time frame:
Weeks 20, 24, 28, 36, and 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI75 Response at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Week 2014.3 (0.0 to 47.4)42.9 (0.0 to 86.7)0 (0.0 to 10.0)0 (0.0 to 25.0)
Week 2450.0 (1.7 to 98.3)42.9 (0.0 to 86.7)75.0 (20.1 to 100.0)0 (0.0 to 25.0)
Week 280 (0.0 to 25.0)50.0 (1.7 to 98.3)66.7 (0.0 to 100.0)0 (0.0 to 50.0)
Week 3666.7 (0.0 to 100.0)40.0 (0.0 to 92.9)50.0 (0.0 to 100.0)0 (0.0 to 50.0)
Week 480 (0.0 to 16.7)20.0 (0.0 to 65.1)25.0 (0.0 to 79.9)0 (0.0 to 50.0)
SecondaryPercentage of Participants Who Achieved Psoriasis Area and Severity Index 90% Improvement (PASI90) Response at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI90, the improvement threshold from baseline in PASI score is 90%. A higher score indicates more severe disease.

Time frame:
Weeks 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90% Improvement (PASI90) Response at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 46.7 (0.0 to 22.6)5.9 (0.0 to 20.0)6.7 (0.0 to 22.6)
Week 813.3 (0.0 to 33.9)5.9 (0.0 to 20.0)0 (0.0 to 3.6)
Week 126.7 (0.0 to 22.6)5.9 (0.0 to 20.0)21.4 (0.0 to 46.5)
Week 1628.6 (1.3 to 55.8)11.8 (0.0 to 30.0)7.1 (0.0 to 24.2)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.0 · 95% CI -24.5 to 24.595% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: -0.8 · 95% CI -23.9 to 22.495% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 13.3 · 95% CI -10.8 to 37.495% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 5.9 · 95% CI -11.8 to 23.695% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: -14.8 · 95% CI -46.6 to 17.195% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: -15.5 · 95% CI -46.3 to 15.295% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 21.4 · 95% CI -13.0 to 55.895% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 4.6 · 95% CI -22.3 to 31.595% CI for difference in response rates were based on normal approximation method with a continuity correction.
SecondaryPercentage of Participants Who Achieved PASI90 Response at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI90, the improvement threshold from baseline in PASI score is 90%. A higher score indicates more severe disease.

Time frame:
Weeks 20, 24, 28, 36, and 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI90 Response at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Week 200 (0.0 to 7.1)14.3 (0.0 to 47.4)0 (0.0 to 10.0)0 (0.0 to 25.0)
Week 2433.3 (0.0 to 79.4)14.3 (0.0 to 47.4)0 (0.0 to 12.5)0 (0.0 to 25.0)
Week 280 (0.0 to 25.0)16.7 (0.0 to 54.8)0 (0.0 to 16.7)0 (0.0 to 50.0)
Week 360 (0.0 to 16.7)0 (0.0 to 10.0)0 (0.0 to 12.5)0 (0.0 to 50.0)
Week 480 (0.0 to 16.7)0 (0.0 to 10.0)25.0 (0.0 to 79.9)0 (0.0 to 50.0)
SecondaryPercentage of Participants Who Achieved Psoriasis Area and Severity Index 100% Improvement (PASI100) Response at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI100, the improvement threshold from baseline in PASI score is 100%. A higher score indicates more severe disease.

Time frame:
Weeks 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Psoriasis Area and Severity Index 100% Improvement (PASI100) Response at Weeks 4, 8, 12, and 16 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline
percentage of participantsFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Week 40 (0.0 to 3.3)5.9 (0.0 to 20.0)0 (0.0 to 3.3)
Week 86.7 (0.0 to 22.6)5.9 (0.0 to 20.0)0 (0.0 to 3.6)
Week 120 (0.0 to 3.3)5.9 (0.0 to 20.0)0 (0.0 to 3.6)
Week 160 (0.0 to 3.6)5.9 (0.0 to 20.0)0 (0.0 to 3.6)
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.0 · 95% CI -6.7 to 6.795% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 5.9 · 95% CI -11.6 to 23.395% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 6.7 · 95% CI -12.9 to 26.295% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 5.9 · 95% CI -11.8 to 23.695% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.0 · 95% CI -6.9 to 6.995% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 5.9 · 95% CI -11.8 to 23.695% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 0.0 · 95% CI -7.1 to 7.195% CI for difference in response rates were based on normal approximation method with a continuity correction.
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · Difference in response rates: 5.9 · 95% CI -11.8 to 23.695% CI for difference in response rates were based on normal approximation method with a continuity correction.
SecondaryPercentage of Participants Who Achieved PASI100 Response at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline

PASI is assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent \[%\] to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI100, the improvement threshold from baseline in PASI score is 100%. A higher score indicates more severe disease.

Time frame:
Weeks 20, 24, 28, 36, and 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI100 Response at Weeks 20, 24, 28, 36, and 48 in Participants With Psoriasis Covering ≥ 3% of the BSA at Baseline
percentage of participantsFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Week 200 (0.0 to 7.1)14.3 (0.0 to 47.4)0 (0.0 to 10.0)0 (0.0 to 25.0)
Week 240 (0.0 to 8.3)14.3 (0.0 to 47.4)0 (0.0 to 12.5)0 (0.0 to 25.0)
Week 280 (0.0 to 25.0)16.7 (0.0 to 54.8)0 (0.0 to 16.7)0 (0.0 to 50.0)
Week 360 (0.0 to 16.7)0 (0.0 to 10.0)0 (0.0 to 12.5)0 (0.0 to 50.0)
Week 480 (0.0 to 16.7)0 (0.0 to 10.0)25.0 (0.0 to 79.9)0 (0.0 to 50.0)
SecondaryChange From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index at Weeks 4, 8, 12, and 16 in Participants With Enthesitis at Baseline

The enthesitis examination is based on the 16 anatomical sites: the medial epicondyle (left and right), the lateral epicondyle (left and right), the supraspinatus insertion (left and right), the bilateral greater trochanter (left and right), the quadriceps tendon insertion into superior border of patella (left and right), the patellar ligament insertion into inferior pole of patella or tibial tuberosity (left and right), the achilles tendon insertion (left and right), and the plantar fascia insertion (left and right). Enthesitis at each site is scored as either 0 (enthesitis absent) and 1 (enthesitis present). SPARCC enthesitis index has an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis. A negative change from baseline indicates improvement.

Time frame:
Baseline, 4, 8, 12, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index at Weeks 4, 8, 12, and 16 in Participants With Enthesitis at Baseline
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 4-2 ± 3.8-2 ± 2.30 ± 2.7
Change from Baseline at Week 8-2 ± 4.9-2 ± 3.2-1 ± 1.9
Change from Baseline at Week 12-2 ± 5.1-3 ± 3.2-1 ± 2.8
Change from Baseline at Week 16-2 ± 5.6-3 ± 2.9-2 ± 2.2
SecondaryChange From Baseline in SPARCC Enthesitis Index at Weeks 20, 24, 28, 36, and 48 in Participants With Enthesitis at Baseline

The enthesitis examination is based on the 16 anatomical sites: the medial epicondyle (left and right), the lateral epicondyle (left and right), the supraspinatus insertion (left and right), the bilateral greater trochanter (left and right), the quadriceps tendon insertion into superior border of patella (left and right), the patellar ligament insertion into inferior pole of patella or tibial tuberosity (left and right), the achilles tendon insertion (left and right), and the plantar fascia insertion (left and right). Enthesitis at each site is scored as either 0 (enthesitis absent) and 1 (enthesitis present). SPARCC enthesitis index has an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis. A negative change from baseline indicates improvement.

Time frame:
Baseline, 20, 24, 28, 36, and 48 weeks
Reported as:
Mean · score on a scale
Change From Baseline in SPARCC Enthesitis Index at Weeks 20, 24, 28, 36, and 48 in Participants With Enthesitis at Baseline
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 20-3 ± 5.2-4 ± 3.60 ± 2.40 ± 1.1
Change from Baseline at Week 24-3 ± 5.3-3 ± 4.30 ± 0.4-1 ± 0.8
Change from Baseline at Week 28-3 ± 6.9-5 ± 5.40 ± 1.70 ± 0.8
Change from Baseline at Week 36-4 ± 5.3-5 ± 5.30 ± 2.11 ± 1.7
Change from Baseline at Week 48-6 ± 5.3-6 ± 5.8-1 ± 1.00 ± 2.0
SecondaryChange From Baseline in Leeds Dactylitis Index (LDI) at Weeks 4, 8, 12, and 16 in Participants With Dactylitis at Baseline

LDI quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with an at least 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, values from a standard reference table. LDI measures the ratio of the circumference of affected digit to circumference of digit on contralateral hand or foot using a Leeds Dactylometer. LDI score is calculated based on circumference of the dactylitic finger/toe (mm), circumference of the contralateral digit (mm), tenderness score (0 = no tenderness, 1 = tender). Tenderness of affected digits is assessed on a scale from 0 (no tenderness) to 3 (tender and withdrawn). A higher LDI indicates worse dactylitis. Negative change from baseline indicates improvement.

Time frame:
Baseline, 4, 8, 12, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Leeds Dactylitis Index (LDI) at Weeks 4, 8, 12, and 16 in Participants With Dactylitis at Baseline
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 4-18.8 ± 48.27-5.3 ± 15.3613.1 ± 70.34
Change from Baseline at Week 8-45.4 ± 88.15-14.4 ± 26.1423.3 ± 129.90
Change from Baseline at Week 12-49.8 ± 85.77-11.8 ± 11.82-15.8 ± 15.82
Change from Baseline at Week 16-42.1 ± 95.15-11.7 ± 6.30-16.2 ± 15.04
SecondaryChange From Baseline in LDI at Weeks 20, 24, 28, 36, and 48 in Participants With Dactylitis at Baseline

LDI quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with an at least 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, values from a standard reference table. LDI measures the ratio of the circumference of affected digit to circumference of digit on contralateral hand or foot using a Leeds Dactylometer. LDI score is calculated based on the circumference of the dactylitic finger/toe (mm), circumference of contralateral digit (mm), tenderness score (0 = no tenderness, 1 = tender). Tenderness of affected digits is assessed on a scale from 0 (no tenderness) to 3 (tender and withdrawn). A higher LDI indicates worse dactylitis. Negative change from baseline indicates improvement.

Time frame:
Baseline, 20, 24, 28, 36, and 48 weeks
Reported as:
Mean · score on a scale
Change From Baseline in LDI at Weeks 20, 24, 28, 36, and 48 in Participants With Dactylitis at Baseline
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 20-79.5 ± 120.99-9.7 ± 6.780.0 ± 0.000.0 ± 0.00
Change from Baseline at Week 24-94.2 ± 125.41-13.0 ± 2.370.0 ± 0.000.0 ± 0.00
Change from Baseline at Week 28-164.6 ± 147.22-11.8 ± 1.640.0 ± 0.000.0 ± NA
Change from Baseline at Week 36-123.4 ± 145.68-11.8 ± 1.640.0 ± NA0.0 ± NA
Change from Baseline at Week 48-123.4 ± 145.68-11.8 ± 1.640.0 ± NA0.0 ± NA
SecondaryChange From Baseline in Tender Dactylitis Count (TDC) at Weeks 4, 8, 12, and 16 in Participants With Dactylitis at Baseline

Tender score (0 = no tenderness, 1 = tender, 2 = tender and wince, 3 = tender and withdraw) is collected for Dactylitis Assessments on the Dactylitis Score Sheet that is used for calculation of LDI total score. Tender dactylitis count (TDC) equals the number of tender fingers and toes (tendor score \>0). For participants with dactylitis status absent for all the fingers and toes, the TDC is set as 0. The total score range of TDC is from 0 to 60, higher scores indicate greater presence of dactylitis. A negative change from baseline indicates improvement.

Time frame:
Baseline, 4, 8, 12, and 16 weeks
Reported as:
Mean · tender dactylitis count
Change From Baseline in Tender Dactylitis Count (TDC) at Weeks 4, 8, 12, and 16 in Participants With Dactylitis at Baseline
tender dactylitis countFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 4-1 ± 2.21 ± 2.70 ± 3.1
Change from Baseline at Week 8-3 ± 5.11 ± 3.71 ± 7.1
Change from Baseline at Week 12-3 ± 5.1-1 ± 0.8-1 ± 1.0
Change from Baseline at Week 16-3 ± 5.3-1 ± 0.5-1 ± 0.8
SecondaryChange From Baseline in TDC at Weeks 20, 24, 28, 36, and 48 in Participants With Dactylitis at Baseline

Tender score (0 = no tenderness, 1 = tender, 2 = tender and wince, 3 = tender and withdraw) is collected for Dactylitis Assessments on the Dactylitis Score Sheet that is used for calculation of LDI total score. Tender dactylitis count (TDC) equals the number of tender fingers and toes (tendor score \>0). For participants with dactylitis status absent for all the fingers and toes, the TDC is set as 0. The total score range of TDC is from 0 to 60, higher scores indicate greater presence of dactylitis. A negative change from baseline indicates improvement.

Time frame:
Baseline, 20, 24, 28, 36, and 48 weeks
Reported as:
Mean · tender dactylitis count
Change From Baseline in TDC at Weeks 20, 24, 28, 36, and 48 in Participants With Dactylitis at Baseline
tender dactylitis countFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 20-5 ± 7.2-1 ± 0.50 ± 0.00 ± 0.0
Change from Baseline at Week 24-6 ± 7.4-1 ± 0.00 ± 0.00 ± 0.0
Change from Baseline at Week 28-10 ± 9.0-1 ± 0.00 ± 0.00 ± NA
Change from Baseline at Week 36-7 ± 8.8-1 ± 0.00 ± NA0 ± NA
Change from Baseline at Week 48-7 ± 8.8-1 ± 0.00 ± NA0 ± NA
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Weeks 2, 4, 8, 12, and 16

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). When 6 or more categories are non-missing, total possible score is 3. If more than 2 categories are missing, the HAQ-DI score is set to missing. A negative change from baseline indicates improvement (less disability).

Time frame:
Baseline, 2, 4, 8, 12, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Weeks 2, 4, 8, 12, and 16
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 2-0.13 ± 0.343-0.04 ± 0.277-0.03 ± 0.228
Change from Baseline at Week 4-0.16 ± 0.320-0.06 ± 0.364-0.07 ± 0.273
Change from Baseline at Week 8-0.29 ± 0.412-0.07 ± 0.471-0.10 ± 0.337
Change from Baseline at Week 12-0.38 ± 0.506-0.15 ± 0.401-0.14 ± 0.342
Change from Baseline at Week 16-0.38 ± 0.489-0.09 ± 0.456-0.08 ± 0.328
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.19 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -0.09 · 95% CI -0.22 to 0.04
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.84 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -0.01 · 95% CI -0.15 to 0.12
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.30 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -0.08 · 95% CI -0.22 to 0.07
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.89 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: 0.01 · 95% CI -0.14 to 0.16
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.064 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -0.18 · 95% CI -0.37 to 0.01
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.88 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: 0.01 · 95% CI -0.17 to 0.20
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.023 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -0.23 · 95% CI -0.43 to -0.03
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.75 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -0.03 · 95% CI -0.23 to 0.17
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.005 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -0.31 · 95% CI -0.51 to -0.10
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.54 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -0.07 · 95% CI -0.27 to 0.14
SecondaryChange From Baseline in HAQ-DI Score at Weeks 18, 20, 24, 28, 36, 48, and 60

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). When 6 or more categories are non-missing, total possible score is 3. If more than 2 categories are missing, the HAQ-DI score is set to missing. A negative change from baseline indicates improvement (less disability).

Time frame:
Baseline, 18, 20, 24, 28, 36, 48, and 60 weeks
Reported as:
Mean · score on a scale
Change From Baseline in HAQ-DI Score at Weeks 18, 20, 24, 28, 36, 48, and 60
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change from Baseline at Week 18-0.42 ± 0.403-0.09 ± 0.481-0.11 ± 0.254-0.02 ± 0.156
Change from Baseline at Week 20-0.38 ± 0.468-0.14 ± 0.573-0.28 ± 0.558-0.02 ± 0.356
Change from Baseline at Week 24-0.21 ± 0.431-0.30 ± 0.546-0.29 ± 0.672-0.11 ± 0.168
Change from Baseline at Week 28-0.23 ± 0.430-0.33 ± 0.485-0.63 ± 0.685-0.13 ± 0.234
Change from Baseline at Week 36-0.36 ± 0.345-0.29 ± 0.417-0.25 ± 0.777-0.20 ± 0.259
Change from Baseline at Week 48-0.41 ± 0.346-0.25 ± 0.428-0.44 ± 0.725-0.04 ± 0.191
Change from Baseline at Week 600.00 ± NA-0.25 ± NA-0.38 ± 0.000-0.19 ± 0.265
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue) Score at Weeks 4 and 16

FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Higher scores indicate less fatigue. Positive change in value indicates improvement (no or less severity of fatigue).

Time frame:
Baseline, 4, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue) Score at Weeks 4 and 16
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 44.8 ± 6.802.3 ± 5.942.5 ± 8.23
Change from Baseline at Week 166.9 ± 11.561.9 ± 7.930.6 ± 11.14
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.43 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: 1.3 · 95% CI -1.9 to 4.5
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.81 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: -0.4 · 95% CI -3.6 to 2.9
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.040 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: 5.1 · 95% CI 0.2 to 9.9
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.58 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: 1.4 · 95% CI -3.4 to 6.1
SecondaryChange From Baseline in FACIT-Fatigue Scale Score at Week 48

FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Higher scores indicate better quality of life. Positive change in value indicates improvement (no or less severity of fatigue).

Time frame:
Baseline, Week 48
Reported as:
Mean · score on a scale
Change From Baseline in FACIT-Fatigue Scale Score at Week 48
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change From Baseline in FACIT-Fatigue Scale Score at Week 486.9 ± 11.274.4 ± 11.765.1 ± 9.093.0 ± 7.63
SecondaryChange From Baseline in Mental Component Score (MCS) of the 36-Item Short-Form Version 2 (SF-36v2) at Weeks 4 and 16

The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consists of social functioning, vitality, mental health, and role-emotional scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. A positive change from baseline indicated improvement (better health status).

Time frame:
Baseline, 4, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Mental Component Score (MCS) of the 36-Item Short-Form Version 2 (SF-36v2) at Weeks 4 and 16
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 41.4 ± 7.911.0 ± 5.07-0.2 ± 8.48
Change from Baseline at Week 163.3 ± 9.841.8 ± 8.120.7 ± 9.43
SecondaryChange From Baseline in MCS of the SF-36v2 at Week 48

The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consists of social functioning, vitality, mental health, and role-emotional scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. A positive change from baseline indicated improvement (better health status).

Time frame:
Baseline, Week 48
Reported as:
Mean · score on a scale
Change From Baseline in MCS of the SF-36v2 at Week 48
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change From Baseline in MCS of the SF-36v2 at Week 482.3 ± 10.551.5 ± 8.74-0.5 ± 4.13-1.4 ± 7.51
SecondaryChange From Baseline in Physical Component Score (PCS) of the SF-36v2 at Weeks 4 and 16

The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). PCS consists of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. A positive change from baseline indicates improvement (better health status).

Time frame:
Baseline, 4, and 16 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Physical Component Score (PCS) of the SF-36v2 at Weeks 4 and 16
score on a scaleFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)
Change from Baseline at Week 42.1 ± 4.952.2 ± 3.920.8 ± 5.61
Change from Baseline at Week 164.6 ± 6.432.6 ± 5.800.6 ± 5.95
Statistical analysis
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.40 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: 0.9 · 95% CI -1.2 to 3.1
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.28 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: 1.2 · 95% CI -1.0 to 3.4
  • Filgotinib 200 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.011 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: 3.8 · 95% CI 0.9 to 6.7
  • Filgotinib 100 mg (Main Study) vs Placebo (Main Study) · MMRM · p = 0.14 (P-value was provided from MMRM including treatment, visit (categorical), treatment by visit, stratification factors, baseline value as fixed effects, participants being the random effect.) · Ls mean treatment difference: 2.1 · 95% CI -0.7 to 5.0
SecondaryChange From Baseline in PCS of the SF-36v2 at Week 48

The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). PCS consists of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. A positive change from baseline indicates improvement (better health status).

Time frame:
Baseline, Week 48
Reported as:
Mean · score on a scale
Change From Baseline in PCS of the SF-36v2 at Week 48
score on a scaleFilgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Change From Baseline in PCS of the SF-36v2 at Week 481.7 ± 7.273.2 ± 7.543.8 ± 8.51-1.9 ± 4.74

Adverse events

Collected over Adverse Events: First dose date up to 63 weeks plus 30 days; All-Cause Mortality: Randomization up to 63 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Filgotinib 200 mg (Main Study)0/36 (0%)1/36 (2.8%)7/36 (19.4%)
Filgotinib 100 mg (Main Study)0/34 (0%)1/34 (2.9%)4/34 (11.8%)
Placebo (Main Study)0/36 (0%)0/36 (0%)9/36 (25%)
Filgotinib 200 mg From Filgotinib 200 mg (LTE)0/18 (0%)1/18 (5.6%)10/18 (55.6%)
Filgotinib 100 mg From Filgotinib 100 mg (LTE)0/20 (0%)1/20 (5%)7/20 (35%)
Filgotinib 200 mg From Placebo (LTE)0/10 (0%)0/10 (0%)5/10 (50%)
Filgotinib 100 mg From Placebo (LTE)0/8 (0%)2/8 (25%)2/8 (25%)
Most frequent serious events
Most frequent serious events
EventFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)Filgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Localised infectionInfections and infestations0/360/340/360/180/200/101/8
DyspnoeaRespiratory, thoracic and mediastinal disorders0/360/340/360/180/200/101/8
Vertigo positionalEar and labyrinth disorders0/360/340/361/180/200/100/8
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/361/340/360/181/200/100/8
Angina unstableCardiac disorders1/360/340/360/180/200/100/8
Most frequent other events
Showing 10 of 40
Most frequent other events
EventFilgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)Filgotinib 200 mg From Filgotinib 200 mg (LTE)Filgotinib 100 mg From Filgotinib 100 mg (LTE)Filgotinib 200 mg From Placebo (LTE)Filgotinib 100 mg From Placebo (LTE)
Covid-19Infections and infestations0/361/342/361/181/201/102/8
DiarrhoeaGastrointestinal disorders1/360/340/360/180/200/101/8
PneumoniaInfections and infestations0/360/341/360/180/200/101/8
SinusitisInfections and infestations0/360/341/360/180/200/101/8
Skin candidaInfections and infestations0/360/340/360/180/200/101/8
Psoriatic arthropathyMusculoskeletal and connective tissue disorders0/360/343/361/181/200/101/8
HypoxiaRespiratory, thoracic and mediastinal disorders0/360/340/360/180/200/101/8
Respiratory distressRespiratory, thoracic and mediastinal disorders0/360/340/360/180/200/101/8
GastroenteritisInfections and infestations0/361/340/362/180/200/100/8
ArthralgiaMusculoskeletal and connective tissue disorders0/360/340/362/181/200/100/8

Baseline characteristics

Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Filgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)Total
Mean56 ± 10.554 ± 9.354 ± 10.555 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Filgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)Total
Female12151845
Male24191861
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Filgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)Total
Hispanic or Latino1315
Not Hispanic or Latino353135101
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Filgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)Total
American Indian or Alaska Native0000
Asian1124
Native Hawaiian or Other Pacific Islander0000
Black or African American0101
White353234101
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Filgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)Total
United States16151445
Poland99927
Spain46717
Czechia2226
Canada2103
Australia1012
Hungary1012
Japan1102
South Korea0011
Taiwan0011
Psoriatic Arthritis Disease Activity Score (PASDAS)
Psoriatic Arthritis Disease Activity Score (PASDAS)(score on a scale)Filgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)Total
Mean5.9 ± 0.975.7 ± 1.075.6 ± 0.935.7 ± 0.99
Disease Activity in Psoriatic Arthritis (DAPSA)
Disease Activity in Psoriatic Arthritis (DAPSA)(score on a scale)Filgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)Total
Mean45.9 ± 22.6442.8 ± 22.0543.1 ± 23.2644.0 ± 22.49
Physician's Global Assessment of Psoriasis (PhGAP)
Physician's Global Assessment of Psoriasis (PhGAP)(score on a scale)Filgotinib 200 mg (Main Study)Filgotinib 100 mg (Main Study)Placebo (Main Study)Total
Mean2.7 ± 0.792.8 ± 0.952.9 ± 0.812.8 ± 0.84

17 further baseline measures are reported on the registry.

08

Study locations

59 sites
  • Medvin Clinical Research
    Covina, California 91723, United States
  • Omega Research Debary, LLC
    DeBary, Florida 32713, United States
  • San Marcus Research Clinic, Inc.
    Miami, Florida 33015, United States
  • Arthritis Center, Inc.
    Palm Harbor, Florida 85234, United States
  • Jefrey D. Lieberman, ND, P.C.
    Decatur, Georgia 30033, United States
  • Bluegrass Community Research, Inc.
    Lexington, Kentucky 40504, United States
  • Klein & Associates, M.D., P.A.
    Hagerstown, Maryland 21740, United States
  • Clinical Research Institute of Michigan, LLC
    Saint Clair Shores, Michigan 48081, United States
  • St. Paul Rheumatology, P.A.
    Eagan, Minnesota 55121, United States
  • Arthritis Consultants, Inc.
    Saint Louis, Missouri 63141, United States
  • Atlantic Coast Research
    Toms River, New Jersey 08755, United States
  • Joint and Muscle Research Institute
    Charlotte, North Carolina 28204, United States
  • Paramount Medical Research & Consulting, LLC
    Middleburg Heights, Ohio 44130, United States
  • Clinical Research Source Inc
    Perrysburg, Ohio 43551, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Arthritis Group, PC
    Philadelphia, Pennsylvania 19152, United States
  • PA Regional Center for Arthritis and Osteoporosis Research
    Wyomissing, Pennsylvania 19610, United States
  • Articularis Healthcare Inc, dba, Columbia Arthritis Center, PA
    Columbia, South Carolina 29204, United States
  • ACME Research, LLC
    Orangeburg, South Carolina 29118, United States
  • Arthritis & Osteoporosis Clinic of Brazos Valley (Drug Shipment Address)
    College Station, Texas 77845, United States
  • Southwest Rheumatology Research, LLC
    Mesquite, Texas 75150, United States
  • West Virginia Research Institute PLLC
    South Charleston, West Virginia 25309, United States
  • Genesis Research Services
    Broadmeadow, New South Wales 2292, Australia
  • Rheumatology Research Unit
    Maroochydore, Queensland 4558, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • CHU UCL Namur - Site Godinne
    Yvoir, 5530, Belgium
  • G.R.M.O. (Groupe de recherche en maladies osseuses) Inc.
    Quebec, G1V3M7, Canada
  • CCR Czech a.s.
    Pardubice, 530 02, Czechia
  • Reumatologie a Osteologie MEDICAL PLUS s.r.o., Rezidence Hradebni, Obchodni 1507, Uherske Hradiste, 68601
    Uherske Hradiste, 68601, Czechia
  • Obudai Egeszsegugyi Centrum Kft.
    Budapest, 1036, Hungary
  • Bekes Megeyi Kozponti Korhaz, Reumatologiai Osztaly
    Gyula, 5700, Hungary
  • Csongrad Megyei Dr. Bugyi Istvan Korhaz, Mozgasszervi Rehabilitacios Osztaly
    Szentes, 6600, Hungary
  • Tokyo Medical University Hachioji Medical Center
    Hachioji-shi, 193-0998, Japan
  • National Hospital Organization Osaka Minami Medical Center
    Kawachinagano, 586-8521, Japan
  • Nagoya City University Hospital
    Nagoya-City, 467-8602, Japan
  • Daido Clinic
    Nagoya, 457-8511, Japan
  • Keio University Hospital
    Tokyo, 160-8582, Japan
  • Inha University Hospital
    Incheon, 22332, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • SMG - SNU Boramae Medical Center
    Seoul, 07061, Korea, Republic of
  • Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk
    Bialystok, Podlaskie, 15-099, Poland
  • NSZOZ Unica CR
    Dabrówka, 62096, Poland
  • Centrum Badan Klinicznych PI-House sp. z o.o
    Gdansk, 80-546, Poland
  • Synexus Polska Sp. z o.o. Oddzial w Katowicach
    Katowice, 40-040, Poland
  • Rheuma Medicus Zaklad Opieki Zdrowotnej
    Warsaw, 02-118, Poland
  • ARS RHEUMATICA Sp. Z.o.o.
    Warszawa, Mazowieckie, 02-691, Poland
  • Centrum Medyczne AMED Warszawa Targowek
    Warszawa, 03-921, Poland
  • Centrum Medyczne Oporow
    Wroclaw, 52-416, Poland
  • Hospital Universitario de Fuenlabrada - Rheumatology Department, Camino Del Molino no 2, Fuenlabrada, Madrid, 28942
    Fuenlabrada, 28942, Spain
  • Hospital Universitario 12 de Octubre, Avenida de Cordoba, s/n, Madrid, Spain, 28041
    Madrid, 28041, Spain
  • Hospital Universitario La Paz. Paseo de la Castellana 261, Madrid, 28046
    Madrid, 28046, Spain
  • Corporacio Sanitaria Parc Tauli, Parc Tauli 1, Rheumatology Service, Sabadell, Barcelona, 08208
    Sabadell, 8208, Spain
  • Hospital Universitario Marques de Valdecilla, Rheumatology Service, Avda. Valdecilla s/n, 39008
    Santander, 39008, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, 41007, Spain
  • Hospital Clinico Universitario de Valencia, Avenida Blasco Ibáñez, 17 Rheumatology Service, Valencia, Spain,
    Valencia, 46010, Spain
  • Buddhist Dalin Tzu Chi Hospital
    Dailin Township, 622, Taiwan
  • Chi Mei Medical Center
    Tainan, 71004, Taiwan
  • Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital
    Taipei, 10507, Taiwan
  • Taipei Medical University Hospital
    Taipei, 11031, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Jan 2021, 13 months.

Results were first posted in Mar 2022, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2019
First posted
Oct 4, 2019
StartActual
Nov 13, 2019
Primary completionActual
Jan 4, 2021
CompletionActual
Mar 18, 2021
Results first posted
Mar 18, 2022
Last update
Mar 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04115839
Lead sponsor
Gilead Sciences
Collaborators
Galapagos NV
Responsible party
Sponsor
First posted
Oct 4, 2019
Start date
Nov 13, 2019
Primary completion
Jan 4, 2021
Completion
Mar 18, 2021
Results posted
Mar 18, 2022
Last update
Mar 18, 2022

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion